
Hold on −5.0% total return: $17.38 target as TI/LC and debt resets cap FAD growth
We initiate at Hold with a $17.38 target, implying −5.0% total return (−10.2% price return). HR owns or holds JV stakes in 560 US medical outpatient buildings (32.8m sf, 73% on/adjacent to campuses). At $19.35, HR trades at 14.1x FY27E FAD vs 12.5x for peers with 3.0% cash growth.
- Campus leasing lifts FY27E NFFO to $1.75 (+3.8% vs $1.69 consensus), our main counter-evidence. Spreads of 8.6% and 88.0% retention add +$0.62/sh vs Street.
- TI, LCs and building capex consume ~16% of NOI, capping FAD conversion at 76%–78%. FY27E FAD is $1.37/sh vs $1.75 FFO; paying 12.5x peer P/AFFO vs 14.1x cuts value by $2.82/sh.
- Resetting $1.75bn of 2.4%–3.75% notes toward 6.0% lifts cash interest 35% by FY30E. Debt resets hold FY27E–30E FAD/sh growth to 3.0%, matching 12.5x peers.
What the market is missing. Street ($21.36 mean; 5B/7H/0S) anchors on 11.4x consensus FY27E P/FFO (11.0x on our $1.75 FFO) or sub-6% private MOB caps (0.89x our $21.68 NAV); $19.35 implies 7.22% FAD growth or a 4.07% 10Y yield.
Catalysts. 8–9 Dec 2026 (9 Dec decision) & Jan 2027 FOMC calls; Feb 2027 FY27 guidance ($1.75E NFFO/sh, 4.5% SS growth); and Jul 2027 $500m note draw onto the ~4.8% delayed-draw loan.
Valuation and target. P/AFFO gives $17.15 base (50%), $14.13 bear (30%) and $19.73 bull (20%), or $16.76 weighted (−13.4%), rolled at 8.88% CAPM less 5.17% yield (3.71%) to $17.38 (0.24x up/down; Low conviction).
Risks. Downside to Hold: 10Y UST +50bp (−$1.01/sh), 17.5% TI/LC (−$0.40/sh), or 3.0% FY27 SS growth (−$0.30/sh) toward our $14.65 bear target; upside: 10Y −50bp (+$1.15/sh) or MOB caps −25bp (+$1.33/sh).
| Dec YE, $m / $/sh | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Normalised FFO ($m) | 576.8 | 568.9 | 579.1 | 595.6 | 607.2 |
| Normalised FFO / sh ($) | 1.56 | 1.61 | 1.67 | 1.75 | 1.82 |
| NFFO / sh growth y/y | −0.6% | +3.2% | +3.6% | +5.1% | +3.8% |
| NAREIT FFO / sh ($) | 0.52 | 1.38 | 1.49 | 1.65 | 1.72 |
| FAD ($m) | – | 448.3 | 441.4 | 465.4 | 482.4 |
| FAD / sh ($) | – | 1.26 | 1.27 | 1.37 | 1.45 |
| GAAP Net income ($m) | −654.5 | −246.1 | −44.6 | 50.8 | 82.8 |
| Dividends / sh ($) | 1.24 | 1.10 | 0.96 | 1.00 | 1.04 |
| At $19.35, 10 Nov 26 | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| P / AFFO (FAD) | – | 15.3x | 15.2x | 14.1x | 13.4x |
| P / FFO (Normalised) | 12.4x | 12.0x | 11.6x | 11.0x | 10.6x |
| EV / Adj. EBITDA | – | – | 15.1x | 14.6x | 14.1x |
| AFFO (FAD) yield | – | 6.5% | 6.6% | 7.1% | 7.5% |
| Dividend yield | 6.4% | 5.7% | 5.0% | 5.2% | 5.4% |
| FAD conversion (% NFFO) | – | 78.8% | 76.2% | 78.1% | 79.5% |
| Net debt / Adj. EBITDA | 6.1x | 5.4x | 5.7x | 5.7x | 5.7x |
| P / AFFO at $17.38 target | – | 13.7x | 13.7x | 12.7x | 12.0x |
Source: Company filings (FY24A–25A; – = FY24A FAD & FY24A–25A Adj. EBITDA not restated post-dispositions); Penmark Research model (E). P/FFO is on Penmark NFFO (11.4x on $1.69 FY27E consensus); Price/NAV at $19.35 is 0.89x ($21.68 Penmark base NAV).
Base-case value is $17.15 (−11.3%) and weighted target is $17.38 (−10.2%), with 0.24x 12-month upside/downside
Source: Yahoo Finance daily closes to 10 Nov 2026; Penmark Research scenarios rolled 12 months at 3.71% (8.88% CAPM less 5.17% forward yield).
10Y UST −50bp (4.48%); spreads 6%–8%, occupancy >94%, FY27E SS growth 5.5%; FY27E FAD $1.43/sh at 13.8x (NAV $24.84).
Price-date 4.98% 10Y UST; SS NOI growth 4.5% fading to 3.25%; re/dev $55.5m by FY29; FY27E FAD $1.37/sh at 12.5x (NAV $21.68).
Fed hikes twice, 10Y +50bp (5.48%); hospital margin squeeze cuts FY27E SS growth to 3.0%; TI/LC 17.5%; FAD $1.29/sh at 10.9x.
| FFO & GAAP, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Same-store NOI | – | 613.3 | 644.9 | 673.9 | 700.9 |
| Total cash NOI | – | – | 684.8 | 716.2 | 746.2 |
| SL rent & other | – | – | 78.8 | 72.0 | 66.9 |
| Normalised G&A | – | −46.3 | −45.0 | −46.6 | −48.2 |
| Cash interest ex-FV | – | – | −139.6 | −146.0 | −157.7 |
| Normalised FFO | 576.8 | 568.9 | 579.1 | 595.6 | 607.2 |
| NAREIT FFO | – | 490.0 | 515.9 | 561.6 | 574.2 |
| GAAP net inc. | −654.5 | −246.1 | −44.6 | 50.8 | 82.8 |
| FAD & cash, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Normalised FFO | 576.8 | 568.9 | 579.1 | 595.6 | 607.2 |
| Maint. capex & LCs | – | −115.6 | −115.0 | −114.6 | −115.7 |
| Straight-line rent | – | −29.4 | −48.3 | −42.0 | −36.0 |
| SBC & non-cash adj. | – | 24.4 | 25.6 | 26.4 | 26.9 |
| FAD (company def.) | – | 448.3 | 441.4 | 465.4 | 482.4 |
| Operating CF | 501.6 | 457.1 | 454.9 | 577.6 | 595.7 |
| Divs & OP dist. | −457.9 | −386.9 | −334.0 | −339.7 | −346.9 |
| FAD less dividends | – | 61.4 | 107.4 | 125.7 | 135.5 |
| Balance sheet, $m | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Cash & equivalents | 68.9 | 26.2 | 20.0 | 20.0 | 20.0 |
| Net RE incl. HFS | 9,327.1 | 7,894.8 | 7,598.4 | 7,230.5 | 6,885.7 |
| JV investments | – | – | 492.0 | 538.7 | 582.7 |
| Total assets | 10,650.9 | 9,210.9 | 8,819.8 | 8,540.6 | 8,275.9 |
| Carrying debt | 4,735.1 | 3,984.6 | 4,198.5 | 4,340.1 | 4,421.0 |
| Consol. debt princ. | – | – | 4,358.5 | 4,460.1 | 4,502.0 |
| Adjusted EBITDA | – | – | 736.1 | 759.6 | 783.4 |
| Total equity | 5,301.1 | 4,673.4 | 4,045.4 | 3,624.5 | 3,278.9 |
| Per share & KPIs | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Diluted shares (m) | 365.6 | 354.5 | 347.1 | 339.7 | 333.6 |
| Norm. FFO / sh ($) | 1.56 | 1.61 | 1.67 | 1.75 | 1.82 |
| FAD / sh ($) | – | 1.26 | 1.27 | 1.37 | 1.45 |
| GAAP EPS ($) | −1.81 | −0.71 | −0.13 | 0.15 | 0.25 |
| Dividends / sh ($) | 1.24 | 1.10 | 0.96 | 1.00 | 1.04 |
| FAD payout (%) | – | 86.3% | 75.7% | 73.0% | 71.9% |
| SS NOI growth | – | +4.8% | +5.15% | +4.50% | +4.00% |
| Net debt / EBITDA | 6.1x | 5.4x | 5.7x | 5.7x | 5.7x |
Source (Exhibits 4–7): Company filings and Q3 2026 supplemental (FY24A–FY25A; – = current 520-property pool lines not restated prior to FY25 dispositions); Penmark Research model (FY26E–FY28E). Scenario probabilities are analyst weights across macro and operating regimes; six robustness checks in Section 15 set Low conviction.
We sit +3.8% above FY27E FFO consensus ($1.75 vs $1.69), yet 78% FAD conversion puts HR at 14.1x cash flow
| Growth & margins | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Growth y/y | |||||
| Same-store cash NOI | – | +4.8% | +5.2% | +4.5% | +4.0% |
| Total cash NOI (incl. JV) | – | – | – | +4.6% | +4.2% |
| Normalised FFO / sh | −0.6% | +3.2% | +3.6% | +5.1% | +3.8% |
| FAD / sh | – | – | +0.5% | +7.8% | +5.6% |
| Dividends / sh | 0.0% | −11.3% | −12.7% | +4.2% | +4.0% |
| Cash conversion and coverage | |||||
| FAD conversion (% NFFO) | – | 78.8% | 76.2% | 78.1% | 79.5% |
| Maint. capex & LCs / NOI | – | 15.8% | 16.8% | 16.0% | 15.5% |
| Total capex / cash NOI | – | – | 49.6% | 43.9% | 35.6% |
| FAD payout ratio | – | 86.3% | 75.7% | 73.0% | 71.9% |
| Adj. EBITDA / cash int. | – | – | 5.3x | 5.2x | 5.0x |
| Scheduled debt coupon | – | – | – | 3.06% | 3.27% |
| Returns, debt & mult. | FY24A | FY25A | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Returns and leverage | |||||
| ROE (GAAP, avg equity) | −10.7% | −4.9% | −1.0% | +1.3% | +2.4% |
| ROA (GAAP, avg assets) | −5.6% | −2.5% | −0.5% | +0.6% | +1.0% |
| ROCE (Adj. EBITDA / cap.) | – | – | 8.7% | 9.4% | 10.0% |
| Carrying debt / equity | 0.89x | 0.85x | 1.04x | 1.20x | 1.35x |
| Net debt / Adj. EBITDA | 6.1x | 5.4x | 5.7x | 5.7x | 5.7x |
| Valuation at $19.35 (10 Nov 26) | |||||
| P / AFFO (FAD) | – | 15.3x | 15.2x | 14.1x | 13.4x |
| P / FFO (Normalised) | 12.4x | 12.0x | 11.6x | 11.0x | 10.6x |
| Price / base NAV ($21.68) | – | – | 0.89x | 0.89x | 0.89x |
| AFFO (FAD) yield | – | 6.5% | 6.6% | 7.1% | 7.5% |
| Dividend yield | 6.4% | 5.7% | 5.0% | 5.2% | 5.4% |
| P / AFFO at $17.38 target | – | 13.7x | 13.7x | 12.7x | 12.0x |
Source (Exhibits 8–9): Company filings (FY24A–FY25A); Penmark Research model (FY26E–FY28E). P/FFO is on Penmark NFFO (11.4x on $1.69 FY27E consensus). GAAP ROE and ROA reflect real-estate D&A ($506.2m FY26E); ROCE = Adjusted EBITDA divided by average carrying debt plus equity (definitions on page 29).
| REIT operating lines | 3Q26A | 4Q26E | FY26E | FY27E |
|---|---|---|---|---|
| Same-store cash NOI ($m; 520-property pool) | ||||
| Penmark / reported | 162.3 | 162.4 | 644.9 | 673.9 |
| Guidance midpoint* | – | 162.1 | 644.7 | 667.3 |
| Prior-year period | 154.4 | 157.0 | 613.3 | 644.9 |
| Diff. vs guide / plan | – | +0.2% | +0.0% | +1.0% |
| Growth y/y (Penmark) | +5.1% | +3.4% | +5.15% | +4.50% |
| Normalised FFO per share ($) | ||||
| Penmark / reported | 0.42 | 0.42 | 1.67 | 1.75 |
| Consensus (Zacks / CapIQ) | 0.41 | 0.40 | 1.65 | 1.69 |
| Prior-year period | 0.41 | 0.40 | 1.61 | 1.67 |
| Diff. vs consensus | +2.4% | +5.5% | +1.1% | +3.8% |
| Growth y/y (Penmark) | +2.4% | +5.5% | +3.6% | +5.1% |
Source: Q3 26 supplemental; Zacks (FY26E $1.65 NFFO; $1,080m rental rev.) & Capital IQ (FY27E $1.69 NFFO; no FY27 rev./EBITDA consensus). *FY26 SS guide 5.125% mid; FY27 at 3.5% plan mid.
Source: Company filings (FY23A–25A); Zacks & Capital IQ consensus; Penmark Research estimates (FY26E–28E).
HR trades +18.0% above peer FY26E P/AFFO (15.2x vs 12.9x) and +0.2 SD above its mean ahead of rate and refi tests
| 10 Nov 26 prices | HR | Peers* | Diff. |
|---|---|---|---|
| Valuation multiples and yields | |||
| P / AFFO (FY26E) | 15.2x | 12.9x | +18.0% |
| P / AFFO (FY27E) | 14.1x | 12.5x | +12.8% |
| P / FFO (FY26E, DOC/NNN) | 11.7x | 11.7x | −0.3% |
| AFFO yield (FY26E) | 6.6% | 7.8% | −1.2pp |
| Dividend yield (FY26E) | 5.0% | 5.6% | −0.7pp |
| Growth, leverage and REIT KPIs | |||
| Medium-term AFFO/FAD gr. | 3.0% | 3.0% | 0.0pp |
| FY26–27E FFO/sh growth | 5.1% | 1.7% | +3.4pp |
| Same-store NOI gr. (vs DOC) | 5.2% | 2.8% | +2.4pp |
| Tenant retention (vs DOC) | 88.0% | 81.7% | +6.3pp |
| Net debt / EBITDA (vs DOC) | 5.5x | 4.7x | +0.8x |
| FAD / AFFO conv. (% FFO) | 76.2% | ~96% | −20pp |
Source: Q3 26 releases, 10 Nov 26 closes, Penmark model. *Peers = 6 IG long-lease REITs (O, ADC, NNN, WPC, BNL, EPRT); FY26E P/FFO uses $1.66 guide midpoint (FFO gr. 5.1% Penmark vs 1.8% Street / 1.7% DOC).
- Dec 26FOMC rate decision (8–9 Dec, call 9 Dec, & Jan 27): tests 4.98% 10Y UST after two Oct hike dissents (−$1.01/sh vs +$1.15/sh).
- Jan 27CY27 OPPS site-neutral rule (1 Jan): −$260m off-campus HOPD imaging cut tests hospital leasing demand.
- Feb 274Q26 results & FY27 guidance: we model $1.75 NFFO/sh (+3.8% vs $1.69 Street) and 4.5% SS NOI growth.
- Jul 27$500m 3.75% notes mature (1 Jul): moves onto delayed-draw loan at SOFR+0.95% (~4.8%) through May 2029.
Source: Federal Reserve, CMS, Q3 2026 supplemental, Penmark Research.
- Fed hikes / 10Y >5.3%. Hurdle +50bp alone cuts peer P/AFFO to 11.8x (10.9x in full bear). Prob. 30%; −$1.01/sh.
- TI/LC stays ≥17.5% NOI. Sustains Q3 26 capex drag (17.4% NOI), depressing FAD. Prob. 40%; −$0.40/sh.
- Hospital margin / OPPS squeeze. Slows FY27E SS growth from 4.5% base to 3.0% (note resets to 6% are already in base). Prob. 35%; −$0.30/sh.
- Upside risk (to Hold): 10Y −50bp or MOB caps −25bp. Lifts P/AFFO or private JV marks. Prob. 20%–30%; +$1.15 to +$1.33/sh.
Source: Penmark Thesis, Market Check & Sensitivities tabs.
Source: Yahoo Finance monthly closes Jan 2023–10 Nov 2026 (n = 47); Penmark FAD series.
Source: Q3 26 guidance & 10 Nov 2026 closes (includes SBRA; NNN, WPC, BNL omitted: FY27 growth n/a).
Six exhibits trace why +3.8% FFO upside still leaves HR 15.4% above probability-weighted cash value ($16.76, −13.4%)
Operational momentum is real, but cash conversion and debt resets eat the FFO beat. Same-store occupancy (+380bp since 1Q25; +330bp since 4Q24) and spreads (8.6% in 3Q26) lift NFFO above consensus, yet ~16% TI/LC drag and a +103bp scheduled coupon step-up cap FY27E–30E FAD/sh growth at 3.0%, leaving 14.1x FY27E P/AFFO rich against 12.5x peers.
Source: Quarterly supplementals & Oct 2026 deck (4Q24 89.8%, 1Q25 89.3% to 3Q26 93.1%; rates dominate weekly R², Sec. 9).
Source: Q3 2026 supplemental (FY25A; 9M26A 16.4%); Penmark Research estimates (FY26E–30E).
Source: Q3 2026 supplemental p19 debt schedule; Penmark Research refinancing model.
Source: Company filings (FY25A); Penmark Research Statements model (FY26E–30E; FY27–30E FAD/sh CAGR 3.0%).
Source: Yahoo Finance monthly closes Jan 2023–10 Nov 2026 (n = 47); Penmark NFFO (11.4x on $1.69 cons.).
Source: Penmark Research scenario model (column widths proportional to 20% / 50% / 30% weights).
Debates 1–3 bridge $19.35 to $16.76 weighted value (−$2.82 multiple, +$0.62 FFO, −$0.39 rates); Debate 4 explains NAV
| Debate | Market view | Penmark view | Evidence & value effect | What changes our view | Resolves |
|---|---|---|---|---|---|
| 1. FY27E FFO & lease-up | $1.69 FY27E NFFO/sh; ~3.5%–4.0% SS NOI growth. | $1.75 FY27E NFFO/sh (+3.8%); 4.5% SS growth & $41m re/dev NOI. | 8.6% 3Q spreads, 88% retention, 480k sf SNO and 72% leased redev add +$0.62/sh vs Street. | CY27 OPPS imaging cuts or hospital delays push FY27 SS growth ≤3.5%. | Feb 2027 |
| 2. Cash multiple: P/FFO vs P/AFFO | Values HR on 11.4x consensus FY27E P/FFO (vs 12.6x net-lease FFO median). | Value on FY27E FAD at 12.5x peer P/AFFO; TI/LC is recurring. | TI/LC & capex consume 15.8%–17.4% of NOI, cutting FAD/sh to $1.37; paying 12.5x peer cash multiple vs 14.1x costs −$2.82/sh. | Lower TI/LC (≤15.0% NOI adds +$0.32/sh; ≤13% NOI lifts FAD conv. >83%). | FY27 prints |
| 3. Rate skew & 2027–30 debt resets | Prices 10 Nov curve (4.98% 10Y) and looks through legacy coupon resets. | 30% bear weight (+50bp 10Y) vs 20% bull; cash interest +35% by FY30E. | Two 28 Oct hike dissents skew hurdle risk (−$0.39/sh); $500m Jul 27 notes draw ~4.8% DDTL before 2028–30 resets at 6.0%. | 10Y UST +50bp (5.48%) cuts P/AFFO to 11.8x (−$1.01/sh); ≤4.48% lifts it to 13.8x. | 9 Dec–Jul 27 |
| 4. Private NAV ($21.68) vs public cash | 0.89x NAV and Healthpeak–Brookfield JV 5.9% cap rates floor HR near $21+. | Public market prices cash FAD yield unless portfolio is liquidated. | 6.28% private cap vs 7.99% public AFFO yield, omitted TI/LC (~$115m/yr) and +$0.77/sh debt mark create the $4.52/sh gap (deducted G&A narrows it). | Large-scale portfolio sale >$750m at ≤5.75% cap or take-private bid. | 2027 deals |
Source: Penmark Research Market Check Section 6 & Thesis tab. Debates 1–3 reconcile $19.35 to $16.76 weighted value (−$2.59/sh net); Debate 4 reconciles the $21.68 NAV cross-check.
Source: Penmark Research sequential debate decomposition.
How the debates map to our chapters & drivers
- Debate 1 → Chapter 10 (p. 15) & Driver 2: Tests our counter-consensus +$0.06/sh FY27E NFFO beat from campus retention, SNO leases and redevelopments.
- Debate 2 → Chapter 11 (p. 16) & Driver 3: Quantifies the ~$115m/yr TI/LC and straight-line rent gap that separates 11.0x P/FFO from 14.1x P/AFFO.
- Debate 3 → Chapter 12 (p. 17) & Driver 1: Links Treasury rate beta and $1.75bn of 2027–30 bond resets to HR’s 3.0% FY27–30E FAD growth ceiling.
- Debate 4 → Chapter 12B (p. 18) & Driver 4: Reconciles private-market NAV ($21.68) with public cash valuation ($17.15 base).
Source: Federal Reserve FOMC calendar; CMS CY27 OPPS final rule (4 Nov 2026); Q3 2026 supplemental debt schedule (full catalyst table on page 24).
Doctors renew 88% of their clinic suites, yet 20 cents of every FFO dollar goes back into TI, commissions and upkeep
Healthcare Realty Trust Incorporated is the largest pure-play landlord of hospital-campus outpatient clinics in the United States. Its buildings enjoy sticky medical demand, but recurring suite refits and expiring 3% debt keep real cash growth well below headline FFO.
The scene
From July through September 2026, hospital systems and physician practices signed ~1.5m square feet of leases across Healthcare Realty’s clinics, renewing 88.0% of expiring suites at 8.6% higher cash rent. That stickiness rests on geography: 73% of its 560 buildings sit directly on or adjacent to hospital campuses, and 93% are affiliated with health systems.
What it actually does
Unlike downtown office towers, outpatient medical buildings house imaging rooms, ambulatory surgery centres, infusion bays and cardiology clinics that cannot work from home. Hospitals lease space to preserve capital for clinical care, and no single tenant exceeds 10% of revenue.
How the money comes in
Multi-year clinic leases carry 64.1 months of remaining term (WALT) and ~2.9% contractual escalators, while 92% of leased space passes operating-cost inflation back to occupants. In FY26E, rents produce $684.8m of cash NOI and $579.1m of Normalised FFO, yet after $115.0m of tenant refits, commissions and capex plus $22.7m net straight-line adjustments, only $441.4m reaches cash (FAD).
Where the story turns
Doubling scale via the 2022 HTA merger collided with rising rates, forcing a dividend reset from $1.24/sh to $0.96/sh. In 2026, CEO Peter Scott completed $187m of sales and loan repayments through October, grew KKR JVs and bought back ~$255m of stock (~14m shares at ~$17.5/sh, incl. 1.5m in Oct at $17.74).
Why it works, and why it might not
Surgeons stay next door to hospital operating rooms, holding same-store occupancy at 93.1%. What breaks the stock is paying 14.1x FY27E cash flow when ~16% NOI capex drag and $1.75bn of 2.4%–3.75% bond resets cap FAD growth at 3.0% (Debates 2 & 3).
Exhibit 26: One outpatient lease cycle, start to finish (3Q26 supplemental & FY26E model).
Same-store outpatient leases generate 94% of HR’s $684.8m FY26E cash NOI, but only 64% ($441.4m) reaches FAD
- Health systems & physician groups
- 91% rated health-system credit affiliation
- 88.0% 3Q26 renewal retention
- 492 wholly owned (28.3m sf)
- 68 JV assets (4.5m sf; KKR/inst.)
- 73% on/adj. campus; 78% top-20 MSA
- 68.2% net/abs. net; 24.9% mod. gross
- 2.9% contractual escalators
- +8.6% 3Q26 cash spreads (5.3% YTD)
- $644.9m same-store (94.2%)
- $32.4m re/dev & completions
- +$2.0m JV acq.; +$5.5m net sales
- −$139.6m cash interest
- −$14.5m G&A net of $30.5m fees
- −$115.0m TI, LCs & bldg capex
- $579.1m Norm. FFO ($1.67/sh)
- $441.4m FAD ($1.27/sh; 76.2% conv.)
- $334.0m div. ($0.96/sh); $107.4m kept
Source: FY2025 Form 10-K; Q3 2026 supplemental; Penmark FY26E model. Bridge: $684.8m cash NOI − $269.1m net cash out + $25.6m non-cash FAD items = $441.4m FAD ($48.3m SL rent cancels).
Source: Penmark Research FY26E Statements & Portfolio model (flows proportional to FY26E $m).
What HR leases, and why health systems renew
Outpatient suites anchor hospital referral ecosystems rather than discretionary desk space. Multi-tenant MOBs represent ~94% of square footage, housing surgery, diagnostics and specialty practices tied to adjacent hospitals, keeping 3Q26 same-store occupancy at 93.1% (+200bp y/y) vs 91.2% total portfolio occupancy (91.3% wholly owned).
Pricing, 92% expense recovery and contractual escalators
Expense pass-throughs insulate NOI margins from property-tax and utility inflation. Roughly 68.2% of leases are net/absolute net and 24.9% modified gross (6.9% gross), letting HR recover ~92% of operating costs while 2.9% annual escalators and 8.6% 3Q26 renewal spreads compound top-line rent.
Cash versus FFO: the structural ~16% TI/LC toll
Multi-tenant medical space is far more capital-intensive than single-tenant net lease. Second-generation TI ($26.2m in 9M26), leasing commissions ($39.0m, +62% y/y on heavy leasing) and building capital ($19.0m) totalled $84.2m in 9M26 (16.4% of cash NOI) and $115.6m in FY25 (15.8%).
Campus adjacency (73% of MOBs) and 11%–14% staggered lease roll lift FY27E cash NOI +4.6% to $716.2m
Source: Penmark Research FY27E Portfolio & Statements model; shaded blue nodes denote Section 14 forecast drivers.
Source: Q3 2026 supplemental (560 total properties at 30 Sep 2026).
Source: Q3 2026 supplemental p12 (total portfolio at share; remaining WALT 64.1 months).
Geographic density & institutional JV platform
Top-20 MSAs contribute 78% of cash NOI, led by Dallas, Seattle, Houston, Charlotte and Denver. Clustering multiple MOBs around single hospital campuses lowers property-management overhead and lets HR move growing physician practices within the same campus rather than losing them on expiry.
Joint ventures extend scale without public equity issuance. HR holds 68 properties (4.52m sf) in unconsolidated JVs, including its expanding KKR partnership ($211m gross acquired in 3Q26; $42m HR share), earning ~$22m/yr of asset- and property-management fees.
Re/development pipeline: $53m–$58m stabilised NOI
Non-stabilised projects provide HR’s main bridge above 2.9% contractual escalators. At 3Q26, HR carried 24 redevelopment projects (2.16m sf, 72% leased, 69.0% occupied, $285.7m budget, $160.1m cost to complete) targeting $46m–$50m stabilised NOI, plus developments (224k sf, 63% leased, $12.7m to complete) targeting $7m–$8m.
Every lease roll carries both spread upside and commission cost. Rolling 10.5%–13.6% of square footage annually lets HR capture 5%–8% cash spreads, but requires recurring TI allowances ($20–$45/sf on new leases) and broker fees.
62.8m older Americans (18.4% of U.S. population) support outpatient demand, while public MOBs trade 87bp wide of core JVs
Source: FY2025 Form 10-K; Q3 2026 supplemental; Penmark Research FY26E model.
Source: World Bank World Development Indicators (U.S. population aged 65+, 2022–2025).
Source: Q3 2026 supplemental & call; CBRE; Cushman & Wakefield; Penmark Market Check & Valuation tabs.
Demographics, site-of-care shift & tight supply
Aging demographics and insurer cost push steadily move procedures out of inpatient beds. U.S. residents aged 65+ grew by +6.3m from 2022 to 62.8m in 2025 (18.39% of the population, +147bp in three years), supporting higher outpatient visit intensity while elevated construction and 6%+ financing costs suppress speculative MOB supply.
Fragmented ownership & institutional JV arbitrage
Public REITs own a minority of U.S. outpatient space; hospitals and physicians still hold the majority. Management puts core campus MOB cap rates at 5.5%–6.0% and core-plus at 6.0%–6.5%, versus 6.80%–7.15% broad broker averages and HR’s 6.77% public implied cap, explaining why HR sells wholly owned assets at mid-5% yields and buys inside 20%-share JVs.
Who earns the margin in the value chain
Rent is a small, senior operating cost for health systems, but contractors capture ~16% of landlord NOI on turnover. While 91% rated health-system affiliation shields HR from direct clinical credit losses, multi-tenant suite customization transfers ongoing TI and commission costs onto the REIT.
Regulatory & reimbursement threats
CMS site-neutral rules and Medicaid reform pressure hospital outpatient margins at the edge. Expanded CY27 OPPS site-neutral payment cuts on off-campus imaging/clinic services and potential federal Medicaid reductions do not void existing leases, but could slow health-system expansion and shave ~150bp off FY27E same-store growth in our bear case (−$0.30/sh).
HR beats Healthpeak on outpatient retention (88.0% vs 81.7%), yet ranks last against net-lease peers on cash retention
Source: Company filings; Healthpeak (DOC) quarterly KPIs; Penmark Research assessment.
Source: HR 3Q26 SS occupancy & retention; DOC 3Q26 retention & 2Q26 outpatient occupancy; Yahoo Finance & Peers tab.
| Dimension | Weight | HR (Pure-play MOB) | Healthpeak (DOC) | Long-lease REITs (O/ADC/NNN) | Health-system ownership |
|---|---|---|---|---|---|
| Campus adjacency & hospital ties | 25% | #1 · 73% campus / 93% affil. | #2 · 506 outpatient MOBs | #4 · Off-campus retail/ind. | #1 · Direct hospital control |
| Pure-play outpatient focus | 15% | #1 · ~100% outpatient MOB | #2 · Mixed w/ lab & CCRC | #4 · Diversified commercial | #3 · Tied to single system |
| Switching costs & retention | 20% | #1 · 88.0% 3Q (90.6% YTD) | #2 · 81.7% 3Q26 retention | #1 · ~85%–99% long-term NNN | #1 · Captive clinics |
| Cash conversion (AFFO/FAD % FFO) | 25% | #4 · 76.2% (TI/LC ~16% NOI) | #3 · Lab/MOB capex drag | #1 · ~95%+ (tenant pays capex) | #3 · Full capex on system BS |
| Valuation & FY26E dividend yield | 15% | #4 · 15.2x AFFO / 5.0% yld | #2 · 11.5x FFO / 6.0% yld | #1 · 12.9x med. AFFO / 5.6% yld | N/A · Tax-exempt bond funded |
Source: Company filings; Healthpeak (DOC) quarterly KPI disclosures; Penmark Research Peers & Methodology tabs.
Evidence the campus moat lasts operationally
Multi-building campus clusters create real tenant switching costs. Because HR owns 560 MOBs concentrated across 49 markets (78% of NOI in top-20 MSAs), expanding specialty groups can add suites on-campus without disrupting hospital admitting privileges. That drove 90.6% YTD retention, +5.3% YTD cash spreads (+8.6% in 3Q26) and +380bp SS occupancy gains since 1Q25 (+330bp since 4Q24).
Direct competitors and self-ownership substitute
HR’s closest public peer is Healthpeak (DOC; 506 outpatient MOBs), alongside private REITs, institutional JVs (KKR, Brookfield) and hospitals themselves. When hospitals enjoy low tax-exempt municipal yields, they occasionally buy back on-campus clinics, a long-term external-growth headwind worth −$0.10/sh in our bear sensitivities.
Why operational superiority has not beaten peers
Public equity investors price net cash yield, not gross leasing spreads. Despite HR beating DOC by +630bp on 3Q26 outpatient retention (88.0% vs 81.7%) and +240bp on reported occupancy (93.1% SS vs DOC’s 90.7% 2Q26 outpatient occupancy), HR trailed DOC by −817bp over 12 months (+7.1% vs +15.3% price return) and offers 102bp less FY26E dividend yield (5.0% vs 6.0%).
Why long-lease REITs set the cash benchmark
Long-lease peers (O, ADC, NNN, WPC, BNL, EPRT) deliver the same 3.0% AFFO/sh growth at 12.9x FY26E AFFO vs HR’s 15.2x. Unlike triple-net landlords whose tenants fund roof and interior upkeep, HR must spend ~$115m/yr on second-generation TI, commissions and building capital just to hold occupancy and capture spreads.
New leadership delivered three FY26 raises and ~$255m of YTD buybacks, but cash bonuses omit FAD/sh
| Executive | Role, tenure & prior background | Shares | Value ($m) | 2026 target pay | Incentive metrics |
|---|---|---|---|---|---|
| Peter A. Scott (46) | President & CEO (Apr 2025); ex-Healthpeak CFO | 592,451 | $11.46m | $6.00m | Cash: 50% NFFO/sh, 20% SS NOI; LTI: 70% rel. TSR |
| Daniel Gabbay (46) | EVP & CFO (Jan 2026); ex-RBC / Barclays RE IB | 191,158 | $3.70m | $2.50m | Cash: 50% NFFO/sh, 20% SS NOI; LTI: 60% rel. TSR |
| Robert E. Hull (53) | EVP & COO (Oct 2024; at HR since 2004) | 297,338 | $5.75m | $2.65m | Cash: 50% NFFO/sh, 20% SS NOI, 30% indiv. |
| Ryan E. Crowley (43) | EVP & CIO (Oct 2024; at HR since 2006) | 198,504 | $3.84m | $2.39m | Cash: 50% NFFO/sh, 20% SS NOI, 30% indiv. |
| Andrew E. Loope (57) | EVP, General Counsel & Sec. | 184,486 | $3.57m | $2.39m | Cash: 50% NFFO/sh, 20% SS NOI, 30% indiv. |
| Execs & directors (13) | 0.56% of shares; 1-yr declassified board terms | 1,946,693 | $37.67m | $15.92m (5 NEOs) | Zero FAD/sh or TI/LC cap in annual cash plan |
Source: FY2025 Form 10-K Item 10; DEF 14A filed 7 Apr 2026 (beneficial ownership at 26 Mar 2026 valued at $19.35; target pay for five NEOs).
Source: Q3 2026 10-Q (9M26; Capex & JVs nets +$8.3m other inv.; Net debt & fin. nets −$52.8m other fin.).
Source: Q3 2026 supplemental (29 Oct 2026) & Guidance tab.
Governance, board & Form 4 insider activity
Clean REIT governance with one-share-one-vote common stock and annual director elections. No controlling holder exists; dedicated REIT and index institutions lead ownership (Cohen & Steers 16.05%, Vanguard 14.05%, BlackRock 11.50% in the April 2026 proxy).
Open-market Form 4 trades skewed modestly toward sales above $19. COO Robert Hull sold 21,000 shares at $19.11 ($401k, 8 Sep 2026) and CAO Amanda Callaway sold 25,767 shares at $20.37 ($525k, 23 Jun 2026), vs director Thomas Bohjalian’s 10,000-share purchase at $18.09 ($181k, 6 Mar 2026).
Capital allocation: reset, JVs & ~$17.5 buybacks
Management’s 2025–26 pivot repaired dividend coverage and shrunk diluted shares by −8.4% since FY23. Resetting the annual dividend from $1.24/sh to $0.96/sh lowered FAD payout from 86.3% in FY25A to 75.7% in FY26E, while $187m of YTD sales and loan repayments through October funded ~$255m of buybacks (~14m shares at ~$17.5/sh, incl. 1.5m in Oct at $17.74; $500m authorization renewed 26 Oct 2026).
Above $19.35, buyback accretion fades sharply. At ~$17.5, repurchases captured a ~7.3% implied cash yield; at $19.35–$20.00, $150m of FY27 buybacks adds just +$0.04/sh vs a zero-buyback baseline.
Four drivers govern HR: sector rates explain 47.9% of weekly moves, while the market under-prices TI/LC cash drag by $2.82/sh
HR trades like a bond-proxy REIT day-to-day, jumps on strategic & FFO guidance raises on earnings days, and ignores its ~16% TI/LC cash leakage. Across four empirical tests (earnings reactions, 1Y/3Y return decomposition, 223-week factor regressions, and 131 call Q&A blocks), four drivers pass at least two tests.
| Driver | What moves the stock | Tests passed | Market reaction vs Penmark model value | Debate | Next number to watch |
|---|---|---|---|---|---|
| 1. REIT beta & 10Y rates | VNQ multiple & 10Y UST shifts; 2027–30 bond resets. | ●●●○ Ret, Factor, Q&A |
S&P 500 + VNQ + 10Y explain 47.9% of weekly variance (VNQ alone 47.6%; 10Y alone 18.4%, slope −0.115); 48 Q&As. Model: +50bp 10Y costs −$1.01/sh (−$0.39/sh skew). | Debate 3: Rate skew |
Dec FOMC & 10Y UST (8–9 Dec; 9 Dec call): 4.98% spot (±50bp = −$1.01/+$1.15). |
| 2. NFFO guide & redev ramp | Quarterly NFFO/sh & SS NOI guidance raises; 72% redev lease-up. | ●●○○ Event, Q&A |
Stock rose +2.0% to +2.9% on 1Q/3Q26 guide raises; 66 Q&As on leasing/redev. Model: FY27E $1.75 NFFO beat adds +$0.62/sh vs Street. | Debate 1: FY27 FFO |
Initial FY27E guide (Feb 2027): we $1.75 NFFO/sh vs $1.69 Street. |
| 3. TI/LC drag & FAD payout | Dividend safety & cash FAD conversion after TI/LC capex. | ●●○○ Ret, Q&A |
Dividends drove +5.5pp of 1Y (+12.6%) & +32.2pp of 3Y (+65.4%) return, yet TI/LC drew only 15 Q&As. Model: peer cash P/AFFO costs −$2.82/sh. | Debate 2: P/AFFO |
FY27E TI/LC guide (Feb 2027): $114.6m (16.0% NOI) vs $105–$125m FY26. |
| 4. Asset sales, JVs & NAV | Mid-5% dispositions, KKR JVs & sub-$18 buybacks. | ●●○○ Event, Q&A |
2Q25 strategic reset jumped +7.68% (7.9m vol.); 43 Q&As. Model: $150m FY27 buybacks at $20 in base (+$0.04/sh vs zero); $21.68 NAV needs buyout. | Debate 4: NAV gap |
JV & sale closings (4Q26–1H27): >$100m under LOI at ~5.5% cap. |
Source: Yahoo Finance; company earnings call transcripts (3Q24–3Q26); Penmark Research model. Filled dots = empirical tests passed out of four.
Source: Yahoo Finance 1-day close-to-close moves (3Q26 also rose +3.4% on 2 Nov).
Source: Yahoo Finance total vs unadjusted price returns through 10 Nov 2026.
| Confirmed driver & linked debate | What $19.35 implies | Model unit sensitivity / base input | Gap ($/sh) | Gap (% of px) |
|---|---|---|---|---|
| Driver 3 · Cash multiple (Debate 2) | 11.4x Street P/FFO (11.0x Penmark; 14.1x P/AFFO) | 12.5x peer P/AFFO (±0.5x = ±$0.69/sh) | −$2.82 | −14.6% |
| Driver 2 · FY27E NFFO & redev (Debate 1) | $1.69 Street FY27E NFFO/sh (~$1.32 FAD) | $1.75 NFFO/sh ($1.37 FAD; +1pp SS = +$0.93/sh) | +$0.62 | +3.2% |
| Driver 1 · Rate & refi skew (Debate 3) | Symmetric curve (4.07% implied 10Y) | 30% bear / 20% bull (+50bp 10Y = −$1.01/sh) | −$0.39 | −2.0% |
| Driver 4 · Recycling & NAV (Debate 4) | 0.89x Penmark $21.68 NAV | Ongoing REIT (−25bp cap = +$1.33/sh on NAV) | $0.00 | 0.0% |
| Total price-to-value gap ($19.35 vs $16.76) | Current share price: $19.35 (10 Nov) | Weighted value: $16.76 ($17.38 12M target) | −$2.59 | −13.4% |
Source: Penmark Research Market Check, Scenarios & Sensitivities tabs (see page 6 for full sequential debate bridge).
Analysts asked 48 questions on debt/rates and just 15 on TI/LC, matching where the stock misprices cash
Source: Yahoo Finance weekly OLS regressions, n = 223 weeks ended 10 Nov 2026.
Source: Company earnings call transcripts across six calls (3Q24–3Q26; 131 Q&A paragraphs).
REIT rate beta & bond resets drive the multiple
Market reaction: Weekly VNQ beta explains 47.6% of HR variance and 10Y UST yields explain 18.4% standalone (slope −0.115); debt/rates drew 48 Q&As with hedged coupon answers.
Model vs price & watchpoint: $19.35 implies a 4.07% 10Y yield vs 4.98% spot (−$0.39/sh skew; −$0.46/sh embedded reset). Watch: 9 Dec 2026 FOMC & Jul 2027 $500m note move to the ~4.8% DDTL (until May 2029).
NFFO raises & 72% leased redevs lift earnings
Market reaction: HR gained +2.9% (1Q26) and +2.0% (+3.4% day-2 in 3Q26) on NFFO/SS NOI raises; leasing (34) and redev (32) drew confident management commentary.
Model vs price & watchpoint: Our $1.75 FY27E NFFO/sh beats $1.69 Street, adding +$0.62/sh (+3.2%). Watch: Feb 2027 initial FY27E guide (we $1.75 vs $1.69 Street; ~2%–4% stock move).
~16% TI/LC drag caps FAD & dividend growth
Market reaction: Dividends delivered +32.2pp of HR’s +65.4% 3Y return, yet after the FY25 dividend reset to $0.96, TI/LC drew just 15 of 131 Q&A blocks (2 in 3Q26).
Model vs price & watchpoint: Paying 12.5x peer P/AFFO instead of 14.1x (11.4x consensus P/FFO; 11.0x Penmark) cuts value by −$2.82/sh (−14.6%). Watch: FY27E TI/LC guide (we $114.6m / 16.0% NOI).
Mid-5% sales & JVs help below $18, stall near $20
Market reaction: HR surged +7.68% on 2Q25’s asset-sale/buyback overhaul and slipped −2.42% on 2Q26 disposition timing; capital allocation drew 43 Q&As.
Model vs price & watchpoint: $150m of FY27 buybacks at $20 (already in base) adds +$0.04/sh vs zero; public shares do not capture $21.68 NAV without M&A. Watch: >$100m LOI sales closing in 4Q26–1Q27.
| Candidate driver | Tests passed | Why it does not explain HR’s share price |
|---|---|---|
| Broad equity market (S&P 500) | ●○○○ Factor (weak) | S&P 500 explains only 9.8% of weekly variance and adds 0.00% incremental R² once VNQ (47.6%) is included. |
| GAAP net income & EPS | ○○○○ None | GAAP EPS stayed negative (−$1.81 FY24, −$0.71 FY25, −$0.18 9M26) on $564m+ D&A while HR rallied; zero Q&As. |
| Tenant credit defaults / bad debt | ○○○○ None | 91% rated health-system affiliation and zero ≥10% tenants kept bad debt immaterial; only 8 Q&As across 6 calls. |
Source: Penmark Research empirical driver screen (Yahoo Finance through 10 Nov 2026; company filings & earnings transcripts).
1. What the market believes
Sell-side consensus ($1.69 FY27E NFFO/sh) extrapolates pre-3Q26 run rates, while bulls at $19.35 assume FFO upside alone justifies the stock. Reverse-solving $19.35 on cash flow requires +233bp/yr higher same-store cash NOI growth across every year of FY27E–30E (starting at 6.83% in FY27E vs our 4.50% base case).
2. Three independent sources of evidence
- Reported KPIs (Q3 10-Q & Supplemental): 3Q26 same-store cash NOI rose +5.1% y/y ($162.3m vs $154.4m) as SS occupancy climbed +200bp y/y (91.1% to 93.1%), retention held at 88.0% (90.6% YTD) and cash spreads reached +8.6% (+380bp q/q).
- SNO & redevelopment schedule: HR ended 3Q26 with >480,000 sf of signed-not-occupied leases and 24 redevelopments 72% leased (+500bp q/q; 69.0% occupied) targeting $46m–$50m stabilised NOI ($53m–$58m incl. developments).
- Peer & call cross-check: HR’s 88.0% 3Q26 outpatient retention beat Healthpeak’s 81.7% by +630bp, while management confirmed 3.0%+ escalators on new leases (supporting our 2.9% blended same-store escalator assumption).
Source: Q3 2026 supplemental; Penmark Portfolio tab forecasts (FY26E–30E).
| Metric | FY26E | FY27E | FY28E | FY29E |
|---|---|---|---|---|
| Normalised FFO/sh, Penmark ($) | 1.67 | 1.75 | 1.82 | 1.88 |
| Normalised FFO/sh, consensus ($) | 1.65 | 1.69 | – | – |
| Penmark vs consensus (%) | +1.1% | +3.8% | – | – |
| Same-store cash NOI growth (%) | 5.15% | 4.50% | 4.00% | 3.50% |
| Re/dev & completions NOI ($m) | 32.4 | 41.0 | 50.0 | 55.5 |
| FAD/sh, Penmark ($) | 1.27 | 1.37 | 1.45 | 1.51 |
Source: Capital IQ / Zacks consensus; Penmark Research Portfolio & Statements tabs.
3. What it is worth per share
Our +$0.06/sh FY27E NFFO beat translates into $1.37/sh of FY27E FAD and adds +$0.62/sh (+3.2%) vs consensus in our base valuation ($17.15 vs $16.53). Within that base case, our $41.0m FY27E redevelopment ramp already captures +$0.17/sh above the $35.5m 3Q run-rate, 4.50% SS growth captures +$0.20/sh above the 3.5% plan midpoint, and $150m FY27 buybacks capture +$0.04/sh vs zero.
4. Dated signposts to watch
- Feb 2027 (4Q26 release): Initial FY27E NFFO/sh guidance ≥$1.73 and SS NOI growth ≥4.25% confirm our 4.50% base case (bull 5.5% adds +$0.20/sh; bear 3.0% cuts −$0.30/sh).
- Mid-2027 (1H27 supplementals): Redevelopment occupancy rising from 69.0% toward ≥76% as 72% leased suites commence rent.
1. What the market believes
At $19.35, equity investors screen HR on 11.4x consensus FY27E Normalized FFO ($1.69; 11.0x on Penmark’s $1.75) against a 12.6x Capital IQ net-lease P/FFO median, treating HR as cheap. On peer P/FFO multiples, HR would screen at $19.91–$22.09/sh (Exhibit 68, Tests 7–8). That comparison ignores that single-tenant net-lease REITs convert ~95%+ of FFO into AFFO because tenants pay interior and roof capex, whereas HR converts just 76.2%–78.1%.
2. Three independent sources of evidence
- Quarterly cash supplementals (1Q25–3Q26): Across seven consecutive post-disposition quarters, quarterly Normalized FFO rose to $145.9m in 3Q26 while FAD stayed flat-to-down at $110.2m ($0.32/sh; 75.5% conversion) as maintenance capex & LCs hit $30.1m (17.4% of cash NOI).
- Granular 9M26 capex filings: 9M26 leasing commissions surged +62.4% y/y to $39.0m ($14.6m in 3Q26 vs $7.4m in 3Q25) alongside $26.2m of 2nd-gen TI and $19.0m of building capital, proving that higher leasing volume (1.5m sf in 3Q) requires upfront cash.
- FY26 guidance & peer AFFO spread: Management’s own FY26 maintenance capex/LC guide ($105m–$125m; $115m midpoint = 16.8% of cash NOI) leaves HR at 15.2x FY26E AFFO vs 12.9x for long-lease peers with identical 3.0% cash growth.
Source: Historicals tab & Q3 2026 supplemental (1Q25–3Q26).
3. What it is worth per share
Paying peer-anchored 12.52x FY27E P/AFFO instead of today’s 14.12x cuts equity value from $19.35 to $16.53/sh (−$2.82/sh) on consensus-implied FY27E FAD (~$1.32/sh), and to $17.15/sh (−$2.20/sh) on Penmark’s higher $1.37/sh FAD. Even with TI/LC easing slightly from 16.8% of cash NOI in FY26E to 16.0% in FY27E ($114.6m) and 15.5% in FY28E–30E, FAD conversion peaks at 80.4%; if TI/LC instead holds at 3Q26’s 17.4%–17.5% rate, bear sensitivity shaves a further −$0.40/sh off value.
4. Dated signposts to watch
- Feb 2027 (4Q26 supplement): Full-year FY26 maintenance capex/LC landing near $115m (≥16.5% NOI) and FY27E guide ≥$110m confirm structural drag.
- 2Q27–3Q27 prints: Whether quarterly FAD breaks sustainably above $118m ($0.35/sh) as 480k sf of SNO leases commence cash rent.
Source: Penmark Research Statements & refinancing model (FY26E–30E).
| Tranche | Maturity | Principal | Old cpn | Model refi | Step-up |
|---|---|---|---|---|---|
| Senior notes | Jul 2027 | $500.0m | 3.75% | ~4.8% DDTL | +105bp (6% ’29) |
| Senior notes | Jan 2028 | $300.0m | 3.63% | 6.00% notes | +238bp |
| DDTL takeout | May 2029 | $400.0m | ~4.80% | 6.00% notes | +120bp perm. |
| Senior notes | Feb 2030 | $650.0m | 3.10% | 6.00% notes | +290bp |
| Senior notes | Mar 2030 | $299.5m | 2.40% | 6.00% notes | +360bp |
| 2027–30 notes | 4 tranches | $1,749.5m | ~3.26% | 6.00% perm. | +274bp by ’30 |
Source: Q3 2026 supplemental p19 & Assumptions tab ($700m 3.00% exch. notes due Jan 2032).
1. What the market believes
At $19.35, our reverse-solve shows the stock implicitly prices a 4.07% 10Y Treasury yield (vs 4.98% spot) or 7.22% FY27E–30E FAD growth (vs 3.00% base). Investors treat near-term liquidity ($1.57bn incl. $400m DDTL) as eliminating refinancing drag.
2. Three independent sources of evidence
- Q3 2026 debt schedule: $500m of 3.75% notes due Jul 2027 move onto the ~4.8% DDTL ($400m) until May 2029, while $300m of 3.625% notes (Jan 2028) and $949.5m of 2.40%–3.10% notes (Feb–Mar 2030) reset to 6.00%.
- FOMC & Treasury market pricing: 10Y UST closed at 4.98% on 10 Nov 2026 after two hawkish rate-hike dissents on 28 Oct, justifying our 30% bear (+50bp) vs 20% bull (−50bp) scenario skew.
- Weekly factor regressions: 10Y UST yield changes alone explain 18.4% of HR weekly variance (slope −0.115), confirming duration sensitivity.
Source: Penmark Market Check reverse-solve (*+2.33pp/yr across FY27E–30E vs 4.50% FY27 base).
3. Worth & 4. Signposts
Worth: Embedded coupon resets hold FY27E–30E FAD growth to 3.0% (EBITDA/interest 5.27x to 4.40x), while asymmetric rate risk subtracts −$0.39/sh (−$1.01/sh if 10Y rises +50bp). Signposts: 8–9 Dec 2026 FOMC (9 Dec decision), Jul 2027 DDTL draw (~4.8%) and Jan 2028 $300m note pricing.
Source: Valuation tab NAV build (6.28% operating cap rate; 343.4m diluted sh & OP units).
| Valuation component | Total ($m) | Per share |
|---|---|---|
| Operating real estate ($690.8m NOI @ 6.28% cap) | 10,999.5 | $32.03 |
| Re/dev net ($589.5m), unstab./land ($164.5m) & HFS ($214.5m) | 968.5 | +$2.82 |
| Platform (−$245.8m net G&A; narrows gap) & WC (−$90.9m) | −336.6 | −$0.98 |
| Marked net debt ($4,451.2m less $264.5m debt mark) | −4,186.7 | −$12.19 |
| Base-case NAV cross-check (0.89x at $19.35) | 7,444.8 | $21.68 |
| Private-cap vs AFFO-yield, TI/LC & debt-mark gap | −1,553.1 | −$4.52 |
| Primary base-case P/AFFO value (12.52x FY27E FAD) | 5,891.7 | $17.15 |
Source: Penmark Valuation & Methodology tabs (343.4m diluted sh & OP units; 26.4% gap explained).
1. What the market believes
Sell-side bulls ($21.36 average target; high $24.00) anchor on private-market cap rates (5.5%–6.0% core) and argue 0.89x NAV protects downside. Indeed, making NAV ($21.68/sh; $22.48 rolled) our primary method lifts HR from Hold to Buy (Exhibit 68, Test 6).
2. Three independent sources of evidence
- Private cap rates vs public AFFO yields: Core JVs (Healthpeak–Brookfield 5.90% cap; KKR JVs) capitalize property NOI tightly relative to public REIT AFFO yields (~8.0% at 12.5x). Platform G&A (−$245.8m, −$0.72/sh) is already deducted in NAV and therefore narrows, rather than explains, the $4.52/sh gap.
- Unliquidated TI/LC math: Capitalizing $690.8m of forward NOI at 6.28% ($11,000m) omits ~$115m/yr of recurring TI/LC; deducting TI/LC cuts economic yield on operating value from 6.28% to ~5.23%.
- Below-par debt mark (+$0.77/sh): NAV marks fixed bonds +$264.5m below par (+$0.77/sh), whereas ongoing shareholders repay 100% of par at maturity.
3. What it is worth per share
Without a full entity sale, $150m of FY27 buybacks at $20/sh (already in our base case) adds just +$0.04/sh vs a zero-buyback baseline. Private cap rates compressing 25bp would lift NAV by +$1.33/sh, yet public REITs without an activist or M&A bid continue to price on distributable cash yield.
4. Dated signposts to watch
- 4Q26–1H27 dispositions: Closing the >$100m under contract/LOI at ≤5.5% cap rates and deploying proceeds into debt paydown vs buybacks above $19.
- Strategic / M&A activity: Any portfolio sale >$750m or entity-level approach narrowing the 87bp public-private cap spread.
Dispositions shrank GAAP revenue 12.1% (FY23–25), while non-cash add-backs leave FAD 23.4% below NFFO in 9M26
| Reported metric ($m unless stated) | FY23A | FY24A | FY25A | 9M26A | Comparability & driver note |
|---|---|---|---|---|---|
| Total GAAP revenues ($m) | 1,343.8 | 1,268.3 | 1,180.5 | 847.5 | −12.1% FY23–25 on non-core MOB sales |
| Gross margin ex-D&A (%) | 62.8% | 62.7% | 62.0% | 64.2% | Rev. y/y: −5.6% FY24A, −6.9% FY25A |
| Real estate D&A (consolidated, $m) | 730.7 | 675.2 | 564.0 | 381.9 | Falls with sales; drives GAAP loss |
| GAAP diluted EPS ($/sh) | −$0.74 | −$1.81 | −$0.71 | −$0.18 | Net loss: −$654.5m FY24A, −$246.1m FY25A |
| NAREIT FFO per share ($/sh) | $1.43 | $0.52 | $1.38 | $1.10 | $381.5m 9M26A; FY24 merger charges |
| Normalised FFO ($m) | – | 576.8 | 568.9 | 434.0 | Stable pool cash earnings post-sales |
| Normalised FFO per share ($/sh) | $1.57 | $1.56 | $1.61 | $1.25 | Lifted by ~$255m YTD share buybacks |
| Company FAD ($m) | – | – | 448.3 | 332.4 | 78.8% NFFO conv. FY25A; 76.6% 9M26A |
| Dividends per share ($/sh) | $1.24 | $1.24 | $1.10 | $0.72 | Reset $0.31 to $0.24/qtr in Q3 2025 |
| Same-store cash NOI growth (%) | 2.8% | – | 4.8% | 5.7% | Occupancy +200bp y/y to 93.1% in 3Q26 |
| Maintenance capex & LCs (% cash NOI) | 18.0% | – | 15.8% | 16.4% | $115.6m FY25A; $84.2m 9M26A (+62% LCs) |
| Net debt / Adjusted EBITDA | 6.4x | 6.1x | 5.4x | 5.5x | $1.1bn FY23–25 debt paydown via sales |
Source: FY2023–FY2025 Form 10-K, Q3 2026 Supplemental (pp. 7–8, 14–15, 23), Penmark Historicals tab. Blank (–) = not disclosed on comparable post-disposition pool.
Source: Company filings (A); Penmark Research model Summary (E).
| REIT item | Company accounting / non-GAAP practice | 9M26A / FY26E cash impact | Status |
|---|---|---|---|
| 2nd-gen TI, LCs & capex | Capitalised; excluded from FFO/NFFO and deducted only in FAD. | $84.2m 9M26A (16.4% NOI); $115.0m FY26E. | Flag |
| Stock-based comp (SBC) | Expensed in NFFO ($12.9m 9M26A), then added back in company FAD like peers. | $17.5m FY26E ($0.05/sh); $423.9m FAD ex-SBC. | Flag |
| Straight-line rent | Booked in GAAP & NFFO ahead of cash rent; deducted in FAD. | $36.3m 9M26A ($48.3m FY26E → $36.0m FY28E). | Watch |
| HTA debt FV amortisation | Non-cash July 2022 merger debt mark added back in NFFO. | $30.3m 9M26A ($39.4m FY26E → $22.0m FY30E). | Watch |
| 2032 Exchangeable notes | $700m 3.00% principal cash-settled; capped call up to $27.41/sh. | 0.0m net shares at $19.35; held at par in debt. | Clean |
Source: Q3 2026 Form 10-Q, Q3 2026 Supplemental (p. 8), Penmark Statements & Methodology tabs.
Our read on earnings quality
Normalised FFO ($1.67/sh FY26E) strips out restructuring ($23.8m) and HTA debt marks ($39.4m), yet still overstates distributable cash by 23.8%. Resetting the dividend 22.6% in Q3 2025 ($1.24 to $0.96/sh) lowered the FY26E FAD payout ratio to a sustainable 75.7%.
Cash NOI compounds at 3.9% (FY26E–30E), but straight-line roll-off and debt resets cap FAD/sh growth at 3.0%
Source: Penmark Research Portfolio NOI tab (gross of net disposition drag).
Reasoning for each revenue-equation driver
Following the Section 5 driver tree (Exhibit 29), we build cash NOI from the 520-property same-store pool plus re/development and JV recycling:
- Same-store NOI (+5.15% FY26E → +3.25% FY30E): 480k sf SNO leases, 2.9% contractual escalators and 8.6% Q3 spreads support +4.50% in FY27E before occupancy nears ~94%.
- Re/development ($32.4m → $57.2m): The 2.38m sf pipeline (72% leased; $172.9m to complete) hits HR’s $53–$58m stabilized target by FY29E ($55.5m).
- Recycling (−$0.4m → −$33.8m forgone NOI): $850m of FY26–30E sales fund $75m/yr of HR-share JV deals plus $250m of FY27–28E buybacks.
| $m (HR share, FFO basis) | 9M26A | Q4 26E | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| Same-store cash NOI (520 MOBs) | 482.5 | 162.4 | 644.9 | 673.9 | 700.9 | 725.4 | 749.0 |
| Same-store cash NOI growth y/y | 5.7% | – | 5.15% | 4.50% | 4.00% | 3.50% | 3.25% |
| Re/development & completions NOI | 23.4 | 9.0 | 32.4 | 41.0 | 50.0 | 55.5 | 57.2 |
| JV acq. NOI net of forgone sales | 6.2 | 1.3 | 7.5 | 1.2 | −4.7 | −7.0 | −7.8 |
| Total cash NOI (HR share) | 512.1 | 172.7 | 684.8 | 716.2 | 746.2 | 773.9 | 798.4 |
| Total cash NOI growth y/y | – | – | – | 4.6% | 4.2% | 3.7% | 3.2% |
| Straight-line rent + other/JV fees | 59.3 | 19.5 | 78.8 | 72.0 | 66.9 | 61.8 | 60.8 |
| Less: Normalised G&A (3.5%/yr) | −33.7 | −11.3 | −45.0 | −46.6 | −48.2 | −49.9 | −51.6 |
| Less: Cash interest (ex-HTA FV) | −103.6 | −35.9 | −139.6 | −146.0 | −157.7 | −162.5 | −188.1 |
| Normalised FFO ($m) | 434.0 | 145.0 | 579.1 | 595.6 | 607.2 | 623.3 | 619.5 |
| Non-cash FAD adj. & TI/LC capex | −101.6 | −36.1 | −137.7 | −130.2 | −124.8 | −122.4 | −123.7 |
| Company FAD ($m) | 332.4 | 109.0 | 441.4 | 465.4 | 482.4 | 500.9 | 495.8 |
| FAD conversion (% of NFFO) | 76.6% | 75.1% | 76.2% | 78.1% | 79.5% | 80.4% | 80.0% |
| Normalised FFO per share ($/sh) | $1.25 | $0.42 | $1.67 | $1.75 | $1.82 | $1.88 | $1.87 |
| Company FAD per share ($/sh) | $0.95 | $0.32 | $1.27 | $1.37 | $1.45 | $1.51 | $1.50 |
| Weighted diluted shares (m) | 348.3 | 343.6 | 347.1 | 339.7 | 333.6 | 331.2 | 331.2 |
Source: Q3 2026 Supplemental (9M26A), Penmark Portfolio & Statements tabs (TI/LC capex is $115.0m FY26E, $114.6m FY27E, $115.7m FY28E, $120.0m FY29E, $123.8m FY30E).
Fixed vs variable property and corporate costs
About 92% of leased sf carries expense recovery (68.2% NNN, 24.9% modified gross), protecting 64.2% YTD NOI margins from tax, utility and insurance inflation. Corporate G&A ($45.0m FY26E) grows at 3.5%/yr, while DDTL/bond resets lift cash interest from $139.6m to $188.1m.
Why FY30E FAD/sh dips (−1.0%)
Refinancing $949.5m of 2.40%–3.10% Feb/Mar 2030 notes at 6.00% adds +$25.6m of cash interest in FY30E. Together with straight-line rent tapering ($48.3m to $28.0m) and 15.5% TI/LC ($123.8m), FY27E–30E FAD/sh compounds at 3.00%/yr.
We sit +3.8% above FY27E NFFO consensus ($1.75 vs $1.69), yet ±1pp operating shifts leave value at $15.95–$18.41
| Guided or consensus line | Period | Penmark | Street | Guide / Plan | Gap | Analytical reason for gap vs Street or midpoint |
|---|---|---|---|---|---|---|
| Normalised FFO / share | FY26E | $1.67 | $1.65 | $1.65–$1.67 | +1.1% vs St | Near top of 29 Oct raised guide on Q3 8.6% spreads & Oct buybacks |
| Normalised FFO / share | FY27E | $1.75 | $1.69 | $1.65–$1.85* | +3.8% vs St | Street lags 480k sf SNO lease-up & 7.5m FY27 share buybacks |
| NAREIT FFO / share | FY26E | $1.49 | – | $1.48–$1.52 | −0.9% vs mid | Reflects $39.4m HTA FV interest & $23.8m normalising items |
| GAAP diluted EPS | FY26E | −$0.13 | – | −$0.15 to −$0.11 | +1.2% vs mid | Includes $12.0m Q4 gain on disposition, net of $530.8m D&A |
| Same-store cash NOI growth | FY26E | 5.15% | – | 5.00%–5.25% | +3bp vs mid | 9M26A ran at 5.7% y/y; Q4 26E moderates against 92.1% Q4 25 comp |
| Same-store cash NOI growth | FY27E | 4.50% | – | 3.0%–4.0%* | +100bp vs mid | CFO adds occupancy recapture onto 3–4% base contractual run-rate |
| Maintenance capex & LCs ($m) | FY26E | $115.0m | – | $105–$125m | 0.0% vs mid | $84.2m spent in 9M26A (16.4% of NOI); $30.8m modelled in Q4 |
| Re/dev & 1st-gen capex ($m) | FY26E | $225.0m | – | $225.0m | 0.0% vs mid | $135.7m spent in 9M26A; tapers to $200m FY27E & $150m FY28E |
| Asset sales & loan repayments | FY26E | $300.0m | – | $350.0m | −14.3% vs mid | $187m closed through Oct, >$100m under LOI; $50m slips into FY27E |
| FAD payout ratio | FY27E | 73.0% | – | 75%–80%* | −450bp vs mid | Below plan even with dividend raised +4.2% to $1.00/sh |
| Net debt / Adjusted EBITDA | FY26E | 5.72x | – | 5.25x–5.75x | +0.22x vs mid | Full-year EBITDA & carrying debt vs HR’s Q3 annualised pro forma 5.5x |
Source: Q3 2026 Supplemental (p. 10), Oct 2026 presentation (*3-year plan targets), Capital IQ/MarketBeat consensus, Penmark Guidance tab.
Source: Penmark Sensitivities tab full-model runs (base $17.15 outlined).
Cash, capex, working capital & debt bridge
Even with +$107m to +$143m/yr of post-dividend retained FAD over FY26E–30E, growth capex ($225m tapering to $120m) and JV commitments ($75m/yr) exceed internal cash generation:
- Working capital caveat: 9M26A reported operating cash flow ($317.3m) included ~$97m of working-capital and normalising outflows; FY27E–30E operating cash flow ($577.6m–$618.4m) is modelled on an FFO cash basis assuming zero working-capital swing.
- Balance-sheet funding: Cash is held at a $20.0m policy floor while the $1.5bn revolver and commercial paper programme ($302.5m Q4 26E; $510.9m FY27E; $479.4m FY30E) absorb timing gaps alongside the $400m delayed-draw term loan.
- Operating sensitivity takeaway: Even simultaneous +1.0pp higher same-store growth every year (FY27–30E) and −1.0pp lower TI/LC lifts price-date value to $18.41/sh, still 4.9% below $19.35.
Peer-anchored P/AFFO (12.52x FY27E FAD) yields $17.15 base value and a $17.38 target (−10.2%); NAV ($21.68) cross-checks
Source: Penmark Research Valuation, Scenarios & Market Check tabs.
| Valuation step | Model | Basis |
|---|---|---|
| FY27E FAD per share | $1.37 | $465.4m FAD / 339.7m sh |
| Long-lease FY26E peer P/AFFO | 12.90x | Median: O, ADC, NNN, WPC, BNL, EPRT |
| Rolled FY27E peer P/AFFO | 12.52x | 3.00% peer growth; 10.99% hurdle |
| HR FY27E–30E FAD/sh CAGR | 3.00% | 1.000x 3-yr relative growth factor |
| Base P/AFFO value (price date) | $17.15 | 12.52x FY27E FAD (9.78x P/FFO) |
| Prob.-weighted value (price date) | $16.76 | 30% Bear / 50% Base / 20% Bull |
| Roll-forward (+3.71% net of yield) | +$0.62 | 8.88% CAPM Ke − 5.17% div. yield |
| 12-month target price | $17.38 | −5.0% total ret. (−10.2% px) → Hold |
Source: Penmark Research Valuation tab (10 Nov 2026 cut-off).
Method and why P/AFFO fits
Outpatient medical buildings consume ~16% of cash NOI in recurring TI, leasing commissions and building capital, making P/AFFO on company FAD the clean cash comparator against long-lease REITs. Applying P/FFO as primary ($19.91–$22.09/sh) credits HR for cash reinvested into clinic suites, while peer-anchored P/AFFO adjusted for three-year relative FAD growth captures terminal cash yield directly. Own-history P/AFFO (14.1x vs 13.8x mean) and peer scatter (15.2x FY26E vs 12.9x median) confirm rich cash pricing.
Explaining the +26.4% NAV cross-check gap
Base NAV ($21.68/sh; $7,444.8m equity) exceeds base P/AFFO ($17.15/sh) for three reasons: (1) private MOB buyers capitalise gross NOI at 6.28% (anchored to the Jul 2026 Healthpeak–Brookfield 5.90% JV plus 10Y UST move) vs ~8.0% public AFFO yields; (2) NAV omits ~$115m/yr of TI/LC from property cap rates (deducted G&A narrows the gap); and (3) NAV marks fixed debt +$264.5m (+$0.77/sh) below par.
Source: Penmark Scenarios Grid 1 (base $17.15 at 10.99% / 3.00%).
Source: Penmark Scenarios Grid 3 (base $21.68 at 6.28% / 4.5%).
$17.38 target implies −5.0% total return (Hold, inside ±10.0%); six robustness tests set Low conviction
| Scenario & Section 9 driver assumptions | Prob. | FY27E NFFO | FY27E FAD | Target P/AFFO | Value (10 Nov) | NAV / sh | 12m Target | Price ret. | Case call |
|---|---|---|---|---|---|---|---|---|---|
| Bear: 10Y +50bp; SS +3.0%; TI/LC 17.5%; lease-up +1yr | 30% | $1.68 | $1.29 | 10.95x | $14.13 | $18.85 | $14.65 | −24.3% | Sell |
| Base: Curve rates; SS +4.5% → 3.25%; $55m re/dev FY29 | 50% | $1.75 | $1.37 | 12.52x | $17.15 | $21.68 | $17.79 | −8.1% | Hold |
| Bull: 10Y −50bp; SS +5.5%; >94% occ.; lease-up −1yr | 20% | $1.81 | $1.43 | 13.81x | $19.73 | $24.84 | $20.46 | +5.7% | Hold |
| Probability-weighted call (12-month target) | 100% | $1.74 | $1.36 | 12.34x* | $16.76 | $21.46 | $17.38 | −10.2% | Hold |
| Memo: Grid 2 P/AFFO × FAD/sh range (11.52x–13.52x × $1.30–$1.44) | Low: $15.00 · Base: $17.15 · High: $19.45 | Model thesis range: $15.39–$18.81/sh (base inside) | |||||||
Source: Penmark Scenarios, Sensitivities & Market Check tabs (*implied weighted P/AFFO = $16.76 / $1.36 = 12.34x; weighted scenario-multiple average = 12.31x).
| Robustness test (Market Check Section 4; other inputs at base) | Price-date value | 12m target | Price return | Price-ret. band | Shifts band? |
|---|---|---|---|---|---|
| Reference: Prob.-weighted P/AFFO (price ret. shown; official −5.0% total ret. = Hold) | $16.76 | $17.38 | −10.2% | Sell | Reference |
| Test 1: Hurdle rate −1.0pp (9.99%), target multiple moves with rate | $19.16 | $19.87 | +2.7% | Hold | Yes (1) |
| Test 2: Hurdle rate +1.0pp (11.99%), target multiple moves with rate | $14.90 | $15.45 | −20.2% | Sell | No |
| Test 3: Beta at low end (0.85 vs 0.92 base) on CAPM roll-forward | $16.76 | $17.33 | −10.4% | Sell | No |
| Test 4: Base case standalone (50% case without 30%/20% rate skew) | $17.15 | $17.79 | −8.1% | Hold | Yes (2) |
| Test 5: FY27E dividend held at $0.96/sh (higher net roll-forward) | $16.76 | $17.42 | −10.0%* | Hold | Yes (3) |
| Test 6: Private-market NAV ($21.68/sh at 6.28% cap) as primary | $21.68 | $22.48 | +16.2% | Buy | Yes (4) |
| Test 7: P/FFO on DOC & NNN FY26E average (11.70x) rolled at peer growth | $19.91 | $20.65 | +6.7% | Hold | Yes (5) |
| Test 8: P/FFO on Capital IQ net-lease FY27E median (12.6x) | $22.09 | $22.91 | +18.4% | Buy | Yes (6) |
Source: Penmark Market Check tab Section 4 (10 Nov 2026 share price $19.35; *Test 5 return is −9.98%, inside the −10.0% to +10.0% Hold band).
Total-return band & probability limits
Our $17.38 target implies −5.0% 12-month total return (incl. $1.00/sh FY27E dividend, 5.2% yield), inside Penmark’s ±10.0% Hold band (−10.2% price return shown). Scenario weights (30% Bear / 50% Base / 20% Bull) reflect asymmetric Treasury/refinancing tail risk around a 4.98% 10Y UST; removing that skew (Test 4: Base alone) yields −8.1% price return ($17.79, Hold).
Reverse valuation: what $19.35 implies
Solving for $19.35 one input at a time while holding all other base inputs fixed shows the market is pricing an unrealistic combination: either 14.12x FY27E P/AFFO (a +12.8% premium to long-lease peers despite identical 3.0% cash growth), a 4.07% 10Y UST (−91bp below spot), 7.22%/yr FY27E–30E FAD/sh growth (+422bp above base), or 6.83% FY27E same-store NOI growth (+233bp/yr across FY27E–30E).
Six dated milestones over 14 months test our $17.38 target; FOMC rates and Feb 2027 guidance test our Hold rating
| Date / window | Event | Penmark expects | Market / Street expects | Rating impact |
|---|---|---|---|---|
| 8–9 Dec 26 & Jan 2027 | FOMC rate decisions (9 Dec call) & 10Y (Driver 1) | 10Y UST holds ~4.98% with 30% bear risk >5.30% (−$1.01/sh). | $19.35 price discounts ~4.07% 10Y UST or benign cut path. | Can flip rating |
| 1 Jan 2027 | CMS CY2027 OPPS site-neutral rule (Debate 1) | −$260m HOPD cut manageable inside 4.5% FY27E SS NOI growth. | Headline reimbursement worry on hospital-affiliated tenants. | Neutral |
| Mid-Feb 2027 | Q4 2026 results & initial FY27 guidance (Driver 2 & 3) | $1.75 FY27E NFFO/sh, +4.5% SS NOI, ~$114.6m TI/LC ($1.37 FAD). | $1.69 FY27E NFFO consensus; bulls look for FAD breakout. | Can flip rating |
| 1H 2027 | LOI asset sales & KKR JV closings (Driver 4) | >$100m under LOI closes into FY27 ($200m FY27 sales; mid-5% cap). | $350m full FY26 guide close & rapid accretive buybacks. | Supports Hold |
| Jul 2027 | $500m 3.75% senior notes maturity (Driver 1) | Moves onto $400m DDTL (~4.8% until May 2029) + CP; ~6% in ’29. | Minimal FFO focus until 2028 guidance incorporates coupon reset. | In base case |
| Jan 2028 | $300m 3.625% senior notes maturity (Driver 1) | Refinanced into 6.00% new unsecured notes (+238bp coupon step-up). | Consensus beyond FY27 sparse; 6% refi caps FAD CAGR at 3.0%. | In base case |
Source: Company filings, Q3 2026 Supplemental, Federal Reserve, CMS, Penmark Thesis & Guidance tabs.
Source: Company filings; CMS; Federal Reserve; Penmark Research.
| Driver & latest reading | Next release & date | Hold (±10% total ret.) holds if | Shifts to Sell (<−10%) or Buy (>+10%) if |
|---|---|---|---|
| 1. 10Y UST & REIT hurdle 4.98% spot; 10.99% hurdle | 8–9 Dec 2026 FOMC (9 Dec call); daily UST | 10Y UST tracks ~4.98% curve ($17.79 base target) or −50bp bull (4.48%; $20.46 target). | Two Fed hikes (+50bp 10Y to 5.48%) or +1.0pp hurdle ($15.45 target) push HR to Sell. |
| 2. SS NOI & re/dev lease-up 5.1% SS; 72% re/dev leased | Mid-Feb 2027 (Q4 26 & FY27 guide) | FY27E SS NOI tracks ~4.50% (fading to 3.25% by FY30E) and re/dev NOI hits $41.0m. | Bear slowdown to 3.0% SS growth (−$0.30/sh) & 1-yr lease-up slip pull toward $14.65 (Sell). |
| 3. TI/LC & FAD conversion 16.4% NOI (9M26); 16.0% ’27E | Mid-Feb 2027 (FY27 capex/LC guide) | FY27E maintenance capex & LCs track ~$114.6m (16.0% NOI; 78.1% FAD conversion). | Sustained 17.5% TI/LC (−$0.40/sh) supports $14.65 bear (Sell); 15.0% adds +$0.32/sh (Hold). |
| 4. Share price / MOB M&A $19.35 px; $21.68 NAV | Daily NYSE close; 1H27 LOI sales / JVs | Public market prices HR on cash FAD ($17.38 target; −5.0% total return) without M&A. | Entity buyout or JV monetization near $21.68 base NAV ($22.48 rolled) lifts HR to Buy. |
Source: Penmark Market Check, Scenarios & Sensitivities grids (each driver test holds other model inputs at base).
Macro rates (−$1.01/+$1.15) and private MOB caps (−$1.23/+$1.33) dominate our $17.15 base value and Hold band
| Upside risk above base | Mechanism vs our $17.15 base case | Likelihood | Value / sh | Observable signpost |
|---|---|---|---|---|
| Private MOB cap compression (−25bp) | Core MOB deals tighten from 5.90% toward 5.65% or strategic/JV buyer bids for large portfolio slice near NAV. | Medium | +$1.33 | JV/disposition prints ≤5.65% cap or entity M&A approach. |
| 10-year Treasury rally (−50bp) | 10Y UST drops from 4.98% to 4.48%, cutting peer AFFO hurdle from 10.99% to 10.49% and lifting target multiple to 13.81x. | Medium | +$1.15 | Dovish 9 Dec 2026 / Jan 2027 FOMC & 10Y UST ≤4.48%. |
| SS NOI +1.0pp/yr (FY27–30E) | Spreads hold 6–8% and occupancy passes 94%, lifting FY27E–30E SS path +100bp/yr above our 4.5%→3.25% base. | Low–Med | +$0.93 | Initial FY27 SS guide ≥5.5% and occupancy >94%. |
| Structural TI/LC drop (−1.0pp NOI) | “As-is” renewals cut recurring maintenance capex/LCs by 100bp across FY27E–30E (to 15.0% of FY27E cash NOI). | Low–Med | +$0.32 | FY27 maintenance capex/LC guide ≤15.0% of cash NOI. |
| Full bull-case convergence | 10Y −50bp, 5.5% FY27E SS growth and 1-yr early $55.5m re/dev stabilization lift value to $19.73 ($20.46 rolled). | 20% wt | +$2.57 | 1-yr early $55.5m re/dev ramp alongside 10Y ≤4.48%. |
Source: Penmark Thesis, Scenarios & Sensitivities tabs. Note: Thesis Bull 1 (+$0.17 re/dev vs Q3 run-rate), Bull 2 (+$0.20 4.5% SS vs 3.5% plan) & Bull 3 (+$0.04 buyback) are already inside our $17.15 base.
Source: Penmark Thesis & Scenarios Grid 3 impacts (Note: −$0.46 6% note reset is already inside $17.15 base vs legacy coupons; +$0.20/+$0.17 compare base vs plan/run-rate).
What would push HR out of our Hold band
At $19.35, our $17.38 target implies −5.0% 12-month total return (−10.2% price return), sitting inside Penmark’s ±10.0% Hold band: a +1.0pp higher hurdle rate ($15.45 target) or our 30% bear case ($14.65 target) pushes total return below −10.0% into Sell, while monetization near $21.68 base NAV ($22.48 rolled) clears +10.0% into Buy.
Incremental downside in our 30% Bear ($14.13)
While 6.0% permanent note resets (−$0.46/sh vs old coupons) are already in our base case, two Fed hikes pushing 10Y UST >5.30% (−$1.01/sh), 3.0% FY27 SS growth (−$0.30/sh), 17.5% TI/LC (−$0.40/sh) and a 1-yr lease-up slip drive −24.3% downside to $14.65.
Regulatory, tenant-ownership & key-person risks
CMS reimbursement & health-system insourcing: Site-neutral HOPD imaging cuts and Medicaid pressure can trim hospital tenant expansion (−1.5pp FY27 SS growth: −$0.30/sh), while cash-rich health systems buying back clinic real estate reduce renewal retention (−$0.10/sh).
Leadership transition & building-retrofit ESG
CEO Peter Scott (Apr 2025) and CFO Daniel Gabbay (Jan 2026) have executed cleanly over three quarters, limiting key-person risk. Aging post-HTA MOBs require ongoing HVAC/building capital ($19.0m in 9M26A), directly captured inside our ~$115m–$124m TI/LC/capex line.
Dedicated REIT funds and indexers dominate the register; short interest is 17.0m shares (2.6 days) and 0 of 12 Street analysts rate HR Sell
| Institution / Form 4 filer | Shares | Value ($m) | Filing note |
|---|---|---|---|
| BlackRock, Inc. | 57.05m | 1,150.6 | 11.50% proxy beneficial |
| Cohen & Steers, Inc. | 53.26m | 1,074.3 | 16.05% #1 active REIT |
| The Vanguard Group | 47.67m | 961.5 | 14.05% proxy beneficial |
| State Street Corp. | 16.74m | 337.7 | 5.61% proxy beneficial |
| T. Rowe Price Associates | 16.09m | 324.5 | Active institutional |
| Resolution Capital / APG US | 22.36m | 452.2 | 12.14m + 10.22m global REIT |
| Insiders & directors (13 persons) | 1.95m | 37.7 | 0.56% of common (Mar 26) |
| Form 4: R. Hull / A. Callaway | −46.8k | −0.93 | Sales: Sep ($19.11) / Jun ($20.37) |
| Form 4: T. Bohjalian (Director) | +10.0k | +0.18 | Open-market buy ($18.09, Mar) |
Source: SEC Form 13F (30 Jun 2026; 377.3m aggregate 13F shares double-count lent/shared stock, so % uses DEF 14A); SEC Form 4.
Source: FINRA bi-weekly short-interest settlements (to 30 Oct 2026).
Source: MarketBeat consensus (12 analysts: 5 Buy / 7 Hold / 0 Sell, 4 Nov 2026); Penmark Research.
| 3-month avg. daily value / volume | $87.0m / day (4.74m shares / day) |
| 52-week intraday trading range | $16.31 (29 Jan 2026) – $22.04 (28 Jul 2026) |
| Voting structure & shares | 1 vote/common sh; 343.4m dil. sh & OP units (31 Oct 26; 0.56% insider) |
| Buyback authorization | $500m renewed 26 Oct 2026 (~$255m / ~14m sh YTD @ ~$17.5; 1.5m Oct @ $17.74) |
| Convertible / exchangeable overhang | $700m 3.00% due 2032; capped call to $27.41/sh |
Source: Yahoo Finance (10 Nov 2026); DEF 14A; Q3 2026 Supplemental; Penmark Valuation tab.
Who sets the marginal share price
Dedicated REIT specialists (Cohen & Steers 16.05%, Resolution Capital, APG) and passive REIT/index trackers (Vanguard 14.05%, BlackRock 11.50%, State Street 5.61%) control over 50% of the register. That ownership mix explains why HR’s weekly return correlates 69% with VNQ (VNQ-only R² = 47.6%; multivariate R² = 47.9%) and why HR rallied +12.8% over the month to 10 Nov alongside broader REIT inflows and Q3 leasing strength.
Positioning, short cover & buyback floor
Short interest declined −16.5% from its June 2026 peak (20.32m shares) to 16.96m shares (2.63 days to cover) at 30 Oct 2026, pointing to balanced positioning consistent with our Hold call. Meanwhile, HR repurchased ~$255m (~14m shares) year to date at ~$17.5/sh, including 1.5m shares in October at $17.74, and renewed its $500m repurchase authorization, creating an opportunistic corporate bid below ~$18.
Annual NOI, FFO, FAD, cash flow and balance sheet (FY24A–FY30E): FAD reaches $500.9m in FY29E before FY30E bond resets
| $m, Dec year end (HR share on FFO/NOI) | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| NOI, Normalised FFO & GAAP earnings | |||||||
| Same-store cash NOI (520-property pool) | – | 613.3 | 644.9 | 673.9 | 700.9 | 725.4 | 749.0 |
| Re/development, JV acq. & net disposed NOI | – | – | 39.9 | 42.2 | 45.3 | 48.5 | 49.4 |
| Total cash NOI (incl. JV at share) | – | – | 684.8 | 716.2 | 746.2 | 773.9 | 798.4 |
| Straight-line rent + net other/JV fee income | – | – | 78.8 | 72.0 | 66.9 | 61.8 | 60.8 |
| Normalised G&A | – | – | −45.0 | −46.6 | −48.2 | −49.9 | −51.6 |
| Interest expense ex-HTA fair-value adjustment | – | – | −139.6 | −146.0 | −157.7 | −162.5 | −188.1 |
| Normalised FFO | 576.8 | 568.9 | 579.1 | 595.6 | 607.2 | 623.3 | 619.5 |
| HTA merger FV interest & normalising items | – | – | −63.2 | −34.0 | −33.0 | −32.0 | −22.0 |
| NAREIT FFO | – | – | 515.9 | 561.6 | 574.2 | 591.3 | 597.5 |
| Real estate & JV D&A, net of sale gains | −675.2 | −564.0 | −518.8 | −510.8 | −491.4 | −470.8 | −454.3 |
| GAAP net income (loss) | −654.5 | −246.1 | −44.6 | 50.8 | 82.8 | 120.6 | 143.2 |
| Funds available for distribution (FAD) | |||||||
| Straight-line rent ($48.3m FY26E) + non-cash add-backs | – | – | −22.7 | −15.6 | −9.1 | −2.5 | 0.1 |
| Maintenance capex & leasing commissions (TI/LC) | – | −115.6 | −115.0 | −114.6 | −115.7 | −120.0 | −123.8 |
| Company FAD ($m) | – | 448.3 | 441.4 | 465.4 | 482.4 | 500.9 | 495.8 |
| FAD ex-SBC ($m) | – | – | 423.9 | 447.4 | 463.9 | 481.8 | 476.1 |
| Dividends & OP distributions ($m) | 457.9 | 386.9 | 334.0 | 339.7 | 346.9 | 357.7 | 370.9 |
| FAD payout ratio (%) | – | 86.3% | 75.7% | 73.0% | 71.9% | 71.4% | 74.8% |
Source: FY24–25 Form 10-K; Q3 2026 Supplemental; Penmark Historicals, Portfolio & Statements tabs.
| $m, Dec year end | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| Cash flow statement | |||||||
| Cash from operating activities | 501.6 | 457.1 | 454.9 | 577.6 | 595.7 | 618.4 | 617.2 |
| Capital expenditure (maint. + re/dev) | −319.3 | −342.8 | −321.5 | −314.6 | −265.7 | −240.0 | −243.8 |
| Net cash from investing (incl. sales & JVs) | 900.9 | 710.8 | −78.4 | −189.6 | −190.7 | −215.0 | −218.8 |
| Dividends & distributions paid | −457.9 | −386.9 | −334.0 | −339.7 | −346.9 | −357.7 | −370.9 |
| Net cash from financing (buybacks & debt) | −1,359.3 | −1,210.7 | −382.7 | −388.0 | −405.0 | −403.5 | −398.4 |
| Consolidated balance sheet (period end) | |||||||
| Real estate investments, net (incl. HFS) | 9,327.1 | 7,894.8 | 7,598.4 | 7,230.5 | 6,885.7 | 6,588.5 | 6,313.9 |
| Unconsolidated JVs + cash + other assets | 1,323.9 | 1,316.1 | 1,221.4 | 1,310.1 | 1,390.2 | 1,461.7 | 1,528.8 |
| Total assets | 10,650.9 | 9,210.9 | 8,819.8 | 8,540.6 | 8,275.9 | 8,050.1 | 7,842.6 |
| Consolidated carrying debt | 4,735.1 | 3,984.6 | 4,198.5 | 4,340.1 | 4,421.0 | 4,413.2 | 4,413.7 |
| Consolidated debt principal | – | – | 4,358.5 | 4,460.1 | 4,502.0 | 4,456.2 | 4,428.7 |
| Total equity (incl. non-controlling OP units) | 5,301.1 | 4,673.4 | 4,045.4 | 3,624.5 | 3,278.9 | 3,060.9 | 2,852.9 |
Source: FY24–25 Form 10-K; Q3 2026 Form 10-Q; Penmark Statements tab (ending cash held at $20.0m policy floor FY26E–30E; balance check = $0.0m).
Quarterly KPIs, debt refinancing ladder (30 Sep 2026–FY30E) and per-share valuation ratios at $19.35 and $17.38 target
| Quarterly metric ($m unless stated) | 1Q25A | 2Q25A | 3Q25A | 4Q25A | 1Q26A | 2Q26A | 3Q26A | 4Q26E |
|---|---|---|---|---|---|---|---|---|
| Same-store cash NOI (520-MOB pool) | – | – | 154.4 | 157.0 | 159.2 | 160.9 | 162.3 | 162.4 |
| Total cash NOI incl. JV at share | – | – | 184.4 | 178.5 | 169.7 | 169.9 | 172.5 | 172.7 |
| Normalised FFO ($m) | 137.7 | 143.7 | 145.3 | 142.1 | 144.4 | 143.7 | 145.9 | 145.0 |
| Normalised FFO / sh ($/sh) | $0.39 | $0.41 | $0.41 | $0.40 | $0.41 | $0.41 | $0.42 | $0.42 |
| Company FAD ($m) | 102.2 | 115.4 | 116.9 | 113.9 | 112.9 | 109.4 | 110.2 | 109.0 |
| Same-store cash NOI growth y/y | 2.3% | 5.1% | 5.4% | 5.5% | 6.9% | 5.1% | 5.1% | 3.4%* |
| Same-store occupancy (%) | 89.3% | 90.0% | 91.1% | 92.1% | 92.3% | 92.7% | 93.1% | – |
| Cash leasing spreads (%) | 2.3% | 3.3% | 3.9% | 3.7% | 4.2% | 4.8% | 8.6% | – |
| Tenant retention (%) | 84.8% | 83.1% | 88.6% | 82.7% | 93.5% | 88.5% | 88.0% | – |
Source: Q3 2026 Supplemental; Penmark Historicals & Portfolio tabs (*4Q26E SS NOI $162.39m vs $157.03m 4Q25A = +3.4%; full-year FY26E = +5.15%).
| Debt tranche ($m principal) | 30 Sep 26 | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|
| Senior notes 3.75% due Jul 2027 | 500.0 | 500.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Senior notes 3.625% due Jan 2028 | 300.0 | 300.0 | 300.0 | 0.0 | 0.0 | 0.0 |
| Senior notes 3.10% Feb 30 & 2.40% Mar 30 | 949.5 | 949.5 | 949.5 | 949.5 | 949.5 | 0.0 |
| Senior notes 2.05% & 2.00% due Mar 2031 | 1,099.8 | 1,099.8 | 1,099.8 | 1,099.8 | 1,099.8 | 1,099.8 |
| Exchangeable notes 3.00% due Jan 2032 | 700.0 | 700.0 | 700.0 | 700.0 | 700.0 | 700.0 |
| Term loans ($500m) + mortgages | 523.0 | 506.7 | 500.0 | 500.0 | 500.0 | 500.0 |
| DDTL ($400m at ~4.8%) + 6.00% refi notes | 0.0 | 0.0 | 400.0 | 700.0 | 700.0 | 1,649.5 |
| Revolver & commercial paper | 347.5 | 302.5 | 510.9 | 552.7 | 506.9 | 479.4 |
| Total consolidated debt (+$31.4m JV debt) | 4,419.8 | 4,358.5 | 4,460.1 | 4,502.0 | 4,456.2 | 4,428.7 |
| Cash interest expense ex-FV ($m; *9M26A) | 103.6* | 139.6 | 146.0 | 157.7 | 162.5 | 188.1 |
| Avg. scheduled cash coupon (%) | – | – | 3.06% | 3.27% | 3.39% | 4.08% |
Source: Q3 2026 Supplemental (p. 19); Penmark Statements tab (*9M26A cash interest ex-FV; Jul 2027 $500m notes draw ~4.8% DDTL until May 2029, then 6.00% notes).
| Per-share & ratio metric | FY24A | FY25A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|---|
| Weighted diluted shares incl. OP units (m) | 365.6* | 354.5 | 347.1 | 339.7 | 333.6 | 331.2 | 331.2 |
| Normalised FFO / sh ($/sh) | $1.56 | $1.61 | $1.67 | $1.75 | $1.82 | $1.88 | $1.87 |
| Normalised FFO / sh growth y/y | −0.6% | +3.2% | +3.6% | +5.1% | +3.8% | +3.4% | −0.6% |
| Company FAD / sh ($/sh) | – | $1.26 | $1.27 | $1.37 | $1.45 | $1.51 | $1.50 |
| Dividends / sh ($/sh) | $1.24 | $1.10 | $0.96 | $1.00 | $1.04 | $1.08 | $1.12 |
| Adjusted EBITDA ($m) | – | – | 736.1 | 759.6 | 783.4 | 805.0 | 827.3 |
| Adjusted EBITDA / cash interest (x) | – | – | 5.27x | 5.20x | 4.97x | 4.95x | 4.40x |
| Net debt / Adj. EBITDA (carrying, x) | 6.10x | 5.40x | 5.72x | 5.73x | 5.66x | 5.50x | 5.35x |
| P / AFFO (FAD) at $19.35 price | – | 15.30x | 15.22x | 14.12x | 13.38x | 12.79x | 12.92x |
| P / AFFO (FAD) at $17.38 target | – | 13.74x | 13.67x | 12.69x | 12.02x | 11.49x | 11.61x |
| P / FFO at $19.35 price | 12.40x | 12.02x | 11.60x | 11.04x | 10.63x | 10.28x | 10.34x |
| Dividend yield at $19.35 price | 6.41% | 5.68% | 4.96% | 5.17% | 5.37% | 5.58% | 5.79% |
Source: Penmark Summary, Statements & Valuation tabs (*FY24A GAAP diluted shares; FY25A+ FFO diluted shares incl. OP units; principal net debt/EBITDA is 5.94x FY26E → 5.37x FY30E).
GAAP-to-FAD reconciliation, REIT glossary, ratio definitions, peer selection and model methodology
| $m (HR share for FFO & FAD) | 9M26A | FY26E | FY27E | FY28E | FY29E | FY30E |
|---|---|---|---|---|---|---|
| GAAP net income (loss) incl. non-controlling OP units | −59.8 | −44.6 | 50.8 | 82.8 | 120.6 | 143.2 |
| Add: Consolidated real estate D&A + JV real estate D&A at share, less gains | 441.3* | 518.8 | 510.8 | 491.4 | 470.8 | 454.3 |
| NAREIT FFO ($m) | 381.5 | 515.9 | 561.6 | 574.2 | 591.3 | 597.5 |
| Add: HTA merger debt fair-value amort. ($39.4m FY26E) + normalising items | 52.5 | 63.2 | 34.0 | 33.0 | 32.0 | 22.0 |
| Normalised FFO ($m) | 434.0 | 579.1 | 595.6 | 607.2 | 623.3 | 619.5 |
| Less: Straight-line rent + non-cash add-backs + maintenance capex & LCs | −101.6 | −137.7 | −130.2 | −124.8 | −122.5 | −123.7 |
| Company FAD ($m; equivalent to peer AFFO) | 332.4 | 441.4 | 465.4 | 482.4 | 500.9 | 495.8 |
Source: Q3 2026 Supplemental (p. 8; *9M26A includes $399.6m RE/JV D&A plus $41.7m net impairment/sale adjustments); Penmark Statements tab.
Glossary of company & sector terms
- MOB / Outpatient Medical: Multi-tenant clinic, ASC and diagnostics real estate; 73% of HR’s 560 properties sit on/adjacent to hospital campuses.
- FAD / AFFO: Normalised FFO less straight-line rent and recurring 2nd-gen TI, leasing commissions and building capex, plus SBC/non-cash amortisation.
- Cash leasing spread: Cash rent on renewed/new leases vs expiring cash rent (+8.6% Q3 2026; +5.3% YTD).
- SNO (Signed-Not-Occupied): Executed leases (>480k sf at Q3 26) awaiting buildout before cash rent starts.
- CMS OPPS site-neutral: Medicare rules aligning hospital outpatient department (HOPD) fees with physician clinics.
Methodology, departures & known limits
Archetype: Real assets: pure-play outpatient medical REIT (US$, calendar FY; non-cyclical). Per REIT standard, P/AFFO (FAD) and P/NAV replace P/E and EV/FCF on Pages 1–4.
- Known limits (Methodology tab): (1) Peer FY27 AFFO growth (3.0%) rests on O, ADC & EPRT (NNN, WPC & BNL guide FY26 AFFO only); (2) FY27 consensus FFO ($1.69) is implied from 23 Oct Capital IQ multiple; (3) 2031–32 bond resets ($1.8bn at 2.0–3.0%) fall after our FY30 growth window (captured in NAV debt mark); (4) 5y published beta (0.92) & May 2026 Damodaran ERP (4.24%) drive the CAPM roll-forward.
Primary data sources & cut-off
SEC 10-K/10-Q/DEF 14A, Q3 26 Supplemental & call (29–30 Oct 2026); Yahoo Finance prices & 10Y UST (10 Nov 2026 close); World Bank demographic statistics (context).
| Measure | Definition in Penmark model | Primary tab |
|---|---|---|
| Target P/AFFO (12.52x) | Rolled FY27E peer median P/AFFO (12.52x) adjusted by three-year compounded FAD growth relative to peers | Valuation |
| Hurdle rate (10.99%) | FY27E peer AFFO yield (7.99%) + peer AFFO growth (3.00%); moves 1:1 with 10Y UST shift | Valuation |
| 12m target ($17.38) | Probability-weighted price-date value ($16.76) rolled 12 months at CAPM Ke (8.88%) less forward yield (5.17%) | Valuation |
| Adjusted EBITDA | Normalised FFO + cash interest ex-FV + stock-based compensation ($736.1m FY26E) | Statements |
| FAD conversion / payout | Company FAD / Normalised FFO (76.2% FY26E); Dividends & OP dist. / FAD (75.7% FY26E) | Statements |
| GAAP ROE / ROA & ROCE | GAAP net income / avg. total equity or assets; Adj. EBITDA / avg. (carrying debt + equity) | Statements |
Source: Penmark Research Statements, Valuation & Methodology tabs.
| Peer group / tickers | Business model & comparability rationale | FY26E Multiple | Growth |
|---|---|---|---|
| O, ADC, EPRT (Net lease) | IG net-lease REITs (>$3bn) guiding AFFO; long leases, fixed escalators, low TI/LC. | 13.4x / 15.2x / 13.8x | 2.9%–5.2% |
| NNN, WPC, BNL (Net lease) | IG commercial/retail net-lease REITs; complete our 6-name 12.90x P/AFFO median. | 11.7x / 12.4x / 11.4x | FY27 n/a |
| DOC (Outpatient / Lab / SH) | 506 MOBs + life-science & senior housing; guides FFO ($1.77) but no AFFO (context). | 11.5x P/FFO | 1.7% FFO |
| SBRA, VTR, WELL, CHCT | Excluded from median: 8–15% senior-housing growth (SBRA/VTR/WELL) or no guide (CHCT). | 13.3x–39.2x | 8.0%–15.3% |
Source: Company Q3 2026 guidance releases; Capital IQ / Barchart / TIKR; Penmark Peers & Methodology tabs.
Analyst certification and important disclosures
Ratings
Ratings are based on the total return from the share price to our 12-month price target, including dividends. The price target is weighted across bull, base and bear scenarios.
| Buy | Total return to price target above +10% |
| Hold | Total return to price target from −10% to +10%, inclusive |
| Sell | Total return to price target below −10% |
We review ratings at each set of results and whenever the facts change materially. A share price can move outside its band before the rating changes, and targets may not be reached.
Analyst certification
The Penmark Team certifies that (1) the views in this report accurately reflect its views about the subject company and its securities, and (2) no part of its compensation was, is or will be directly or indirectly related to the specific ratings, price targets or views in this report.
Contact
Penmark Research
Questions about our research:
research@penmarkresearch.com
All our research and coverage:
penmarkresearch.com
Basis of preparation
This report uses information publicly available up to its publication date. Share prices are closing prices on the trading day before the publication date, unless stated otherwise. Forecasts, valuations and price targets are Penmark Research’s own, and forecast periods are marked E. Sources are shown beneath each exhibit.
Valuation and price targets
Price targets are based on the valuation methods set out in each report and are weighted across bull, base and bear scenarios. The main risks to each rating and price target are described in the report. Penmark Research updates its coverage after each set of results but is not obliged to update a report at any other time.
Independence and conflicts of interest
Penmark Research is independent. It does not provide investment banking, brokerage, market-making or asset management services, does not trade securities, and does not accept payment from any company for research coverage. Companies do not see or review Penmark Research reports before publication.
No member of the Penmark Team holds a long or short position, directly or through derivatives, in the securities of any company Penmark Research covers.
Regulatory status
Penmark Research publishes general, impersonal investment research on a regular basis. It is not registered as an investment adviser with the US Securities and Exchange Commission or any state securities authority, is not a registered broker-dealer and is not a member of FINRA. Penmark Research does not give advice tailored to any person’s circumstances.
Not investment advice or an offer
This report is for information only. It is not personalised investment advice and is not an offer or solicitation to buy or sell any security or other financial instrument. It does not take into account any reader’s objectives, financial situation or needs. Readers should make their own investment decisions and seek independent professional advice where appropriate.
Forward-looking statements and risk
Forecasts, valuations and price targets are estimates based on assumptions that may prove wrong, and they may not be achieved. Opinions are current as of the publication date and may change without notice. Investing in equities involves risk, including the loss of capital. Share prices can be volatile, and past performance is not a reliable indicator of future results.
Data and sources
Company financials, operating data and filings come from company filings, earnings releases and earnings calls. Market data and any consensus estimates come from third-party sources named beneath the relevant exhibit; consensus figures from aggregators are unofficial. Penmark Research does not use other brokers’ research. Third-party data belong to their providers and may not be extracted from this report.
Accuracy and liability
Information is taken from sources believed to be reliable, but Penmark Research makes no representation or warranty as to its accuracy, completeness or timeliness. To the fullest extent permitted by law, Penmark Research accepts no liability for any loss arising from use of this report. Descriptions of litigation and regulatory matters reflect allegations and public records, not findings, unless stated. If a published report is corrected, the corrected version carries an “Updated” date at penmarkresearch.com.
Distribution and access
Penmark Research reports are published at penmarkresearch.com. Access, downloads and programmatic use are governed by the Penmark Research terms of use. This report is not directed at, or intended for, any person in Singapore or India, and access from those countries is blocked. It is not intended for distribution to, or use by, any person in any jurisdiction where that would be contrary to law or regulation or would subject Penmark Research to registration or licensing requirements there.
Copyright and permitted use
© Penmark Research. All rights reserved. Penmark Research is a trade name of Brightriver Labs. Readers may share a link to this report but may not copy, reproduce, redistribute, sell or use its content, including for text and data mining, without written consent. Contact: research@penmarkresearch.com.